

# Manuscripts

2020

Black JC, Bau GE, Rosen T, Cepeda MS, Wedin GP, Green JL, Dart RC. Changes in mortality involving extended-release and long-acting opioids after implementation of a Risk Evaluation and Mitigation Strategy. *Pain Med.* 2020 Jan 1;21(1):92-100. DOI: 10.1093/pm/pnz031.

Chan WL, Dargan PI, Haynes CM, Green JL, Black JC, Dart RC, Wood DM. Misuse of prescription medicines is as prevalent as the use of recreational drugs and novel psychoactive substances in Singapore: an unrecognised public health issue? *Singapore Med J.* 2020 Mar 17. https://doi.org/10.11622/smedj.2020024. Epub ahead of print.

Cicero TJ, Ellis MS, Kasper ZA. Polysubstance use: A broader understanding of substance use during the opioid crisis. *Am J Public Health*. 2020; 110:244-250. DOI:10.2105/AJPH.2019.305412.

Ellis MS, Kasper ZA, Cicero TJ. The impact of opioid use disorder on levels of educational attainment: Perceived benefits and consequences. *Drug Alcohol Depend.* 2019 Nov 2. DOI: 10.1016/j.drugalcdep.2019.107618. Epub ahead of print.

Schimmel J, Amioka E, Rockhill K, Haynes CM, Black JC, Dart RC, Iwanicki JL. Prevalence and description of kratom (*Mitragyna speciosa*) use in the United States: A cross-sectional study. *Addiction*. 2020 Apr 14. https://doi.org/10.1111/add.15082. Epub ahead of print.

Wang GS, Olsen HA, Severtson SG, Green JL, Dart RC. The impact of the prescription opioid epidemic on young children: Trends and mortality. *Drug Alcohol Depend*. 2020 Mar 13. https://doi.org/10.1016/j.drugalcdep.2020.107924. Epub ahead of print.

Webb NE, Wood DM, Black JC, Amioka E, Dart RC, Dargan PI. Non-medical use of loperamide in the UK and USA. *QJM.* 2020; 113:25-30. DOI: 10.1093/qjmed/hcz215.

2019


Black JC, Rockhill K, Forber A, Amioka E, May KP, Haynes CM, Dasgupta N, Dart RC. An online survey for pharmacoepidemiological investigation (Survey of Non-Medical Use of Prescription Drugs Program): validation study. *J Med Internet Res* 2019;21(10):e15830. DOI: 10.2196/15830.

Cicero TJ, Mendoza M, Cattaneo M, Dart RC, Mardekian J, Polson M, Roland CL, Schnoll SH, Webster LR, Park PW. Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid noncancer patients. *Postgrad Med J*. 2019 Apr; 131(3):225-229. DOI: 10.1136/postgradmedj-2018-135798.

Dart RC. Commentary on Mintz et al. (2019): Unintended or intended? Coming to grips with the opioid crisis. *Addiction*. 2019 Dec; 114(12):2160-2161.

Dasgupta N, Schwarz J, Hennessy S, Ertefaie A, Dart RC. Causal inference for evaluating prescription opioid abuse using trend-in-trend design. *Pharmacoepidemiol Drug Saf.* 2019 May; 28(5):716-725. DOI: 10.1002/pds.4736.

Ellis MS, Cicero TJ, Dart RC, Green JL. Understanding multi-pill ingestion of prescription opioids: Prevalence, characteristics, and motivation. *Pharmacoepidemiol Drug Saf*. 2019 (1):117-121. DOI: 10.1002/pds.4687.



Hockenhull J, Amioka E, Black JC, Haynes CM, Dargan PI, Dart RC, Wood DM. Nonmedical use of alprazolam in the UK: Results from a nationally representative survey. *Br J Clin Pharmacol*. 2019 Aug; 85(8):1841-1845. DOI: 10.1111/bcp.13959.

Kurtz SP, Buttram ME, Margolin ZR, Wogenstahl K. The diversion of nonscheduled psychoactive prescription medications in the United States, 2002 to 2017. *Pharmacoepidemiol Drug Saf*. 2019 May; 28(5):700-706. DOI: 10.1002/pds.4771.

Lebin JA, Murphy DL, Severtson SG, Bau GE, Dasgupta N, Dart RC. Scoring the best deal: Quantity discounts and street price variation of diverted oxycodone and oxymorphone. *Pharmacoepidemiol Drug Saf.* 2019 Jan; 28(1):25-30. DOI: 10.1002/pds.4558.

Wang GS, Haynes C, Besharat A, Lait ML, Green JL, Dart RC, Roosevelt G. Brief report: Characterization of marijuana use in US college students by state marijuana legalization status as reported to an online survey. *Am J Addict*. 2019 Jul; 28(4):266-269. DOI: 10.1111/ajad.12870

#### 2018

Butler SF, Black RA, Severtson SG, Dart RC, Green JL. Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV® substance use disorder treatment centers and RADARS<sup>®</sup> System Poison Centers. *J Subst Abuse Treat.* 2018; 84:42-49.

Calcaterra SL, Severtson SG, Bau GE, Margolin ZR, Bucher-Bartelson B, Green JL, Dart RC. Trends in intentional abuse or misuse of benzodiazepines and opioid analgesics and the associated mortality reported to poison centers across the United States from 2000 to 2014. *Clin Toxicol*. 2018 Nov; 56(11):1107-1114. DOI: 10.1080/15563650.2018.1457792.

Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: The surging rise of methamphetamine use in chronic opioid users. *Drug Alcohol Depend.* 2018 Dec 1; 193:14-20. DOI: 10.1016/j.drugalcdep.2018.08.029.

Iwanicki JL, Severtson SG, Margolin Z, Dasgupta N, Green JL, Dart RC. Consistency between opioid-related mortality trends derived from poison center and National Vital Statistics System, United States, 2006-2016. *Am J Public Health*. 2018; 108:1639-1645. DOI: AJPH.2018.304728

Murphy DL, Lebin JA, Severtson SG, Olsen HA, Dasgupta N, Dart RC. Comparative rates of mortality and serious adverse effects among commonly prescribed opioid analgesics. *Drug Saf.* 2018 Aug; 41(8): 787-795. DOI: 10.1007/s40264-018-0660-4.

Ng FL, Rockhill K, Black J, May KP, Whittington MD, Wood DM, Dargan PI, Green JL. UK survey of non-medical use of prescription drugs (NMURx) as a valuable source of general population illicit drug use data. *Postgrad Med J*. 2018; 94:627-633. DOI: 10.1136/postgradmedj-2018-135798.

Pouget ER, Fong C, Rosenblum A. Racial/ethnic differences in prevalence trends for heroin use and non-medical use of prescription opioids among entrants to Opioid Treatment Programs, 2005-2016. *Subst Use Misuse*. 2018 Jan 28; 53(2):290-300. DOI: 10.1080/10826084.2017.1334070.

Smith DC, Dart RC, Hirst C. Prevention not Cure: Avoiding a European Prescription Opioid Epidemic. *ONdrugDelivery*. 2018 Jul; 88:4-48. https://www.ondrugdelivery.com/publications/88/Issue\_88\_Hi\_Res.pdf .

Vosburg SK, Severtson SG, Dart RC, Cicero TJ, Kurtz SP, Parrino MW, Green, JL. Assessment of tapentadol API abuse liability with the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System. *J Pain*. 2018 Apr; 19(4):439-453. DOI: 10.1016/j.jpain.2017.11.007.



Wang GS, Severtson SG, Bau GE, Dart RC, Green, JL. Unit-dose packaging and unintentional buprenorphine-naloxone exposures. *Peds*. 2018 Jun; 141(6). DOI: 10.1542/peds.2017-4232.

#### 2017

Bucher Bartelson B, Le Lait MC, Green JL, Cepeda MS, Coplan PM, Maziere JY, Wedin GP, Dart RC. Changes in misuse and abuse of prescription opioids following implementation of Extended-Release and Long-Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy. *Pharmacoepidemiol Drug Saf.* 2017 Sep; 26(9):1069-1070. DOI: 10.1002/pds.4257.

Buttram ME, Kurtz SP, Dart RC, Margolin ZR. Law enforcement-derived data on gabapentin diversion and misuse, 2002-2015: diversion rates and qualitative research findings. *Pharmacoepidemiol Drug Saf.* 2017 Sep; 26(9):1083-1086. DOI: 10.1002/pds.4230.

Cicero TJ, Ellis MS. Understanding the demand side of the prescription opioid epidemic: does the initial source of opioids matter? *Drug Alcohol Depend.* 2017;173:S4-S10. DOI: 10.1016/j.drugalcdep.2016.03.014.

Cicero TJ, Ellis MS, Kasper ZA. Increased use of heroin as an initiating opioid of abuse. *Addict Behav.* 2017 Nov;74:63-66. DOI: 10.1016/j.addbeh.2017.05.030.

Cicero TJ, Ellis MS, Kasper ZA. Increases in self-reported fentanyl use among a population entering drug treatment: the need for systematic surveillance of illicitly manufactured opioids. *Drug Alcohol Depend*. 2017;177:101-103. DOI: 10.1016/j.drugalcdep.2017.04.004.

Cicero TJ, Ellis MS, Kasper ZA. Psychoactive substance use prior to the development of iatrogenic opioid abuse: A descriptive analysis of treatment-seeking opioid abusers. *Addict Behav.* 2017 Feb;65:242-244. DOI: 10.1016/j.addbeh.2016.08.024.

Cicero TJ, Ellis MS, Kasper ZA. Relative preferences in the abuse of immediate-release versus extended-release opioids in a sample of treatment-seeking opioid abusers. *Pharmacoepidemiol Drug Saf.* 2017 Jan; 26(1):56-62.

Dart RC, Iwanicki JL, Dasgupta N, Cicero TJ, Schnoll SH. Do abuse deterrent opioids work? *J Opioid Manag*. 2017 Nov/Dec; 13(6):365-378.

Fonseca F, Torrens M, Farré M, McBride KE, Guareschi M, Touzeau D, Villeger P, Benyamina A, Dagnone O, Somaini L, Maremmani I, Dart RC. Patterns of prescription drug use and misuse in Spain: The European Opioid Treatment Patient Survey. *Heroin Addict Relat Clin Probl.* 2017;19(4):53-56.

Green JL, Bucher Bartelson B, Le Lait MC, Roland CL, Masters ET, Mardekian J, Bailey JE, Dart RC. Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration. *Drug Alcohol Depend.* 2017; 175:140-145. DOI 10.1016/j.drugalcdep.2017.01.039.

Vosburg SK, Haynes C, Besharat A, Green, JL. Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program. *Pharmacoepidemiol Drug Saf*. 2017 Sep; 26(9):1044-1052. DOI: 10.1002/pds.4248.

#### 2016

Cicero TJ, Ellis MS, Kasper ZA. A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs. *Pain.* 2016;157(6):1232-8.



Dart RC, Green JL. The prescription paradox of acetaminophen safety. *Pharmacoepidemiol Drug Saf.* 2016;25(5):599-601.

Dart RC, Surratt HL, Le Lait MC, Stivers Y, Bebarta VS, Freifeld CC, Brownstein JS, Burke JJ, Kurtz SP, Dasgupta N. Diversion and illicit sale of extended release tapentadol in the United States. *Pain Med.* 2016;17(8):1490-1496.

Iwanicki JL, Severtson SG, McDaniel H, Rosenblum A, Fong C, Cicero TJ, Ellis MS, Kurtz SP, Buttram ME, Dart RC. Abuse and diversion of immediate release opioid analgesics as compared to extended release formulations in the United States. *PLoS ONE.* 2016; 11(12): e0167499. DOI:10.1371/journal.pone.0167499

Maremmani I, Somaini L, Deruvo G, Maremmani AGI, Touzeau D, Walcher S, Fonseca F, Bacciardi S, Guareschi M, Green JL, McBride K, Dart RC. Opioid misuse in the 30 days prior to entering Agonist Opioid Treatment in four European Countries. A pilot study. *Heroin Addict Relat Clin Probl.* 2016;18(3):43-52.

Severtson SG, Ellis MS, Kurtz SP, Rosenblum A, Cicero TJ, Parrino MW, Gilbert MK, Buttram ME, Dasgupta N, Bucher Bartelson B, Green JL, Dart RC. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. *Drug Alcohol Depend.* 2016;168:219-229.

West NA, Dart RC. Prescription opioid exposures and adverse outcomes among older adults. *Pharmacoepidemiol Drug Saf.* 2016; 25(5):539-544.

Wiegand TJ, Le Lait MC, Bucher Bartelson B, Dart RC, Green JL. Analysis of the abuse and diversion of the buprenorphine transdermal delivery system. *J Pain.* 2016;17(6):745-752.

#### 2015

Cicero TJ, Ellis MS. Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin. *JAMA Psychiatry*. 2015;72(5):424-430.

Cicero TJ, Ellis MS. Abuse-deterrent formulations of prescription opioids [Letter to the Editor]. *JAMA Psychiatry*. 2015;72(8):850-851.

Cicero TJ, Ellis MS, Harney J. Shifting patterns of prescription opioid and heroin abuse in the United States [Letter to the Editor]. *N Engl J Med.* 2015;373(18):1789-1790.

Dart RC, Surratt HL, Cicero TJ, Parrino MW, Severtson SG, Bucher Bartelson B, Green JL. Trends in opioid analgesic abuse and mortality in the United States. *N Engl J Med.* 2015;372(3):241-8.

Dart RC, Severtson SG, Green JL. Abuse-deterrent formulations of prescription opioids [Letter to the Editor]. *JAMA Psychiatry.* 2015;72(8):849.

Fong C, Matusow H, Cleland CM, Rosenblum A. Characteristics of non-opioid substance misusers among patients enrolling in opioid treatment programs: a latent class analysis. *Journal of Addictive Diseases.* 2015; 34(2-3):141-50.

Maremmani I, Guareschi M, Deruvo G, Somaini L, Maremmani AGI, Green J, McBride K, Dart RC. Prescription opioids (substitution medications and pain medication) in patients looking for Opioid Agonist Treatment in Northern and Southern Italy, using a 18-month survey methodology. *Heroin Addict Relat Clin Probl.* 2015;17(1):33-42.

West NA, Severtson SG, Green JL, Dart RC. Trends in abuse and misuse of prescription opioids among older adults. *Drug Alcohol Depend.* 2015;149:117-21.



#### 2014

Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. *JAMA Psychiatry* 2014;71(7):821-6.

Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. Factors contributing to the rise of buprenorphine misuse: 2008-2013. *Drug Alcohol Depend* 2014;142:98-104.

Dart RC, Bucher Bartelson B, Adams EH. Non-medical use of tapentadol immediate release by college students. *Clinical Journal of Pain.* 2014 Aug;30(8):685-92.

Davis JM, Searles VB, Severtson G, Dart RC, Bucher-Bartelson B. Seasonal variation in suicidal behavior with prescription opioid medicine. *Journal of Affective Disorders*. 2014 Jan;23(1):18-25.

Davis JM, Severtson SG, Bucher-Bartelson B, Dart RC. Using poison center exposure calls to predict prescription opioid abuse and misuse-related emergency department visits. 2013. *Pharmacoepidemiol Drug Saf*. 2014; 23(1):18-25.

Lavonas EJ, Severtson SG, Martinez EM, Bucher-Bartelson B, Le Lait M-C, Green JL, Murrelle L, Cicero TJ, Kurtz SP, Rosenblum A, Surratt HL, Dart RC. Abuse and diversion of buprenorphine sublingual tablets and film. *Journal of Substance Abuse Treatment*. 2014 Jul:47(1):27-34.

Le Lait MC, Martinez EM, Severtson SG, Lavery SA, Bucher-Bartelson B, Dart RC. Assessment of prescription opioid intentional exposures across the rural-urban continuum in the United States using both population and drug availability rates. *Pharmacoepidemiol Drug Saf.* 2014 Dec;23(12):1334-7.

Passik SD. Tamper-resistant opioid formulations in the treatment of acute pain. *Advances in Therapy*. 2014; 31(3):264-275.

Surratt HL, O'Grady C, Kurtz SP, Stivers Y, Cicero TJ, Dart RC, Chen M. Reductions in prescription opioid diversion following recent legislative interventions in Florida. *Pharmacoepidemiol Drug Saf.* 2014 Mar;23(3):314-20.

2013

Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. Factors influencing the selection of hydrocodone and oxycodone as primary opioids in substance abusers seeking treatment in the United States. *Pain*. 2013 Dec;154(12):2693-2648.

Dasgupta N, Freifeld C, Brownstein JS, Menone CM, Surratt HL, Poppish L, Green JL, Lavonas EJ, Dart RC. Crowdsourcing black market pricing of prescription opioids. *Journal of Medical Internet Research*. 2013 Aug;15(8):e178. DOI:10.2196/jmir.2810.

Giraudon I, Lowitz K, Dargan PI, Wood DM, Dart RC. Prescription opioid abuse in the UK [Letter to the Editor]. *British Journal of Clinical Pharmacology*. 2013 Nov;76(5):823-824.

Hoyte CO, Albert D, Heard KJ. The use of energy drinks, dietary supplements, and prescription medications by United States college students to enhance athletic performance. *J Community Health*. 2013; 38:575-580.

Lavonas EJ, Banner W, Bradt P, Bucher-Bartelson B, Brown KR, Rajan P, Murrelle L, Dart RC, Green JL. Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children. *Journal of Pediatrics*. 2013 Nov;163(5):1377-1383.



Sembower MA, Ertischek MD, Buchholtz C, Dasgupta N, Schnoll SH. Surveillance of diversion and nonmedical use of extended-release prescription amphetamine and oral methylphenidate in the United States. *Journal of Addictive Diseases*. 2013 Mar;32(1):26-38.

Severtson SG, Bucher Bartelson B, Davis JM, Muñoz A, Schneider MF, Chilcoat H, Coplan PM, Surratt H, Dart RC. Reduced abuse, diversion, and therapeutic errors following reformulation of OxyContin® in 2010. *The Journal of Pain.* 2013 Oct:14(10):1122-1130.

Smith SM, Dart RC, Katz NP, Paillard F, Adams EH, Comer SD, Degroot A, Edwards RR, Haddox, DJ., Jaffe JH, Jones CM, Kleber HD, Kopecky EA, Markman JD, Montoya ID, O'Brien C, Roland CL, Stanton M, Strain EC, Vorsanger G, Wasan AD, Weiss RD, Turk DC, Dworkin RH. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. *Pain*. 2013 Nov;154:2287-2296.

Zosel A, Bucher Bartelson B, Bailey E, Lowenstein S, Dart R. Characterization of adolescent prescription drug abuse and misuse using the Researched Abuse Diversion and Addiction-Related Surveillance (RADARS®) System. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2013 Feb;52(2):196-204.

### 2012

Cicero TJ, Ellis MS. Health outcomes and motivations of patients using no-prescription online pharmacies to purchase tramadol. *Journal of Medical Internet Research*. 2012(Dec 06);14(6)e174.

Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin [Letter to the Editor]. *New England Journal of Medicine*. 2012 Jul;367(2):187-189.

Cicero TJ, Surratt HL, Kurtz S, Ellis MS, Inciardi JA. Patterns of prescription opioid abuse and comorbidity in an aging treatment population. *Journal of Substance Abuse Treatment*. 2012 Jan;42:87-94.

Dart RC, Cicero TJ, Surratt HL, Rosenblum A, Bartelson BB, Adams EH. Assessment of the abuse of tapentadol immediate release: The first 24 months. *Journal of Opioid Management*. 2012 Nov-Dec;8(6):395-402.

Dasgupta N, Davis J, Funk MJ, Dart R. Using poison center exposure calls to predict methadone poisoning deaths. *PLOSone*. 2012 Jul;7(7):e41181. DOI:10.1371/journal.pone.0041181.

Reifler LM, Droz D, Bailey E, Schnoll SH, Fant R, Dart RC, Bucher Bartelson B. Do prescription monitoring programs impact state trends in opioid abuse/misuse? *Pain Medicine*. 2012 Mar;13:434-442.

#### 2011

Cicero TJ, Ellis MS, Paradis A, Ortbal Z. The role of key informants and direct patient interviews in epidemiological studies of substance abuse. *Pharmacoepidemiol Drug Saf.* 2011;20(3):308-312.

Cicero TJ, Kurtz SP, Surratt HL, Ibanez GE, Ellis MS, Levi-Minzi MA, Inciardi JA. Multiple determinants of specific modes of prescription opioid diversion. *Journal of Drug Issues.* 2011 Spring: 41(2):283-304.

Cleland CL, Rosenblum A, Fong C, Maxwell C. Age differences in heroin and prescription opioid abuse among enrollees into opioid treatment programs. *Substance Abuse Treatment, Prevention, and Policy.* 2011;6(2):11.

Dart RC, Dasgupta N, Bailey JE, Spiller HA. Interpreting poison center call volume associated with tramadol [Letter to the Editor]. *The Annals of Pharmacotherapy*. 2011;45(3):424.



Katz N, Dart RC, Bailey E, Trudeau J, Osgood E, Paillard F. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. *The American Journal of Drug and Alcohol Abuse*. 2011;37:205-217.

Rosenblum A, Cleland CM, Fong C, Kayman DJ, Parrino M. Distance traveled and cross-state commuting to opioid treatment programs in the United States. *Journal of Environmental and Public Health*. 2011;2011:948789.

Surratt H, Kurtz SP, Cicero TJ. Alternate routes of administration and risk for HIV among prescription opioid abusers. *Journal of Addictive Diseases*. 2011:30(4):334-341.

2010

Cicero TJ, Ellis MS, Paradis A, Ortbal Z. Determinants of fentanyl and other potent µ opioid agonist misuse in opioiddependent individuals. *Pharmacoepidemiol Drug Saf*. 2010;19:1057-1063.

Cicero T, Inciardi JA, Surratt HL, Horbay G, Bordman J, Forster I. Characteristics of prescription opioid abuse in the United States and Canada. *Canadian Journal of Addiction Medicine*. 2010;1(2):9-13.

Dasgupta N, Bailey JE, Cicero T, Inciardi JA, Parrino M, Rosenblum A, Dart RC. Post-marketing surveillance of methadone and buprenorphine in the United States. *Pain Medicine*. 2010;11(7):1078-1091.

Inciardi JA, Surratt HL, Cicero TJ, Rosenblum A, Ahwah C, Bailey JE, Dart RC, Burke JJ. Prescription drugs purchased through the internet: Who are the end users? *Drug and Alcohol Dependence*. 2010;110(1-2):21-29.

Lindholm A, Varughese S, Sembower MA, Shiffman S, Schnoll SH, Ertischek MD, St. Jean E, Rosen S. Current trends in nonmedical use of prescription extended-release amphetamines and methylphenidate. *European Psychiatry*. 2010;25ns1:648.

Smith MY, Rosenblum A, Parrino M, Fong C, Colucci S. Validity of self-reported misuse of prescription opioid analgesics. *Substance Use and Misuse*. 2010;45:1509-1524.

Spiller H, Bailey JE, Dart RC, Spiller SS. Investigation of temporal changes of abuse and misuse of prescription opioids. *Journal of Addictive Disease*. 2010;29:78-83.

#### 2009

Bailey JE, Campagna E, Dart RC, Reporting for the RADARS<sup>®</sup> System Poison Center Group. The underrecognized toll of prescription opioid abuse on young children. *Annals of Emergency Medicine*. 2009;53:419-424.

Dart RC. Monitoring risk: Post marketing surveillance and signal detection. *Drug and Alcohol Dependence*. 2009;105(S1):S26–S32.

Inciardi JA, Surratt HL, Cicero TJ, Beard RA. Prescription opioid abuse and diversion in an urban community: The results of an ultrarapid assessment. *Pain Medicine*. 2009;10(3):537-548.

Inciardi JA, Surratt HL, Cicero TJ, Kurtz SP, Martin SS, Parrino MW. The 'black box' of prescription drug diversion. *Journal of Addictive Diseases*. 2009;28(4):332-347.

Inciardi JA, Surratt HL, Stivers Y, Cicero TJ. FDA approvals of generic drugs: Impact on the diversion of opioid analgesics with a potential for abuse. *Journal of Opioid Management.* 2009;5(2):81-87.



Maxwell JC, McCance-Katz EF. Indicators of buprenorphine and methadone use and abuse: What do we know? *The American Journal on Addictions*. 2009;19:73–88.

Schneider, MF, Bailey, JE, Cicero TJ, Dart RC, Inciardi JA, Parrino M, Munoz A. Integrating nine prescription opioid analgesics and/or four signal detection systems to summarize statewide prescription drug abuse in the United States in 2007. *Pharmacoepidemiol Drug Saf.* 2009;18(9):778-790.

Spiller H, Lorenz DJ, Bailey JE, Dart, RC. Epidemiological trends in abuse and misuse of prescription opioids. *Journal of Addictive Diseases*. 2009;28:130-136.

2008

Hayes BD, Klein-Schwartz W, Doyon S. Toxicity of buprenorphine overdoses in children. *Pediatrics*. 2008;121:782-786.

Smith MY, Irish W, Wang J, Haddox J, Dart RC. Detecting signals of opioid analgesic abuse: Application of a spatial mixed effect poisson regression model using data from a network of poison control centers. *Pharmacoepidemiol Drug Saf.* 2008;17:1050-1059.

#### 2007

Cicero TJ, Dart RC, Inciardi JA, Woody GE, Schnoll S, Munoz A. The development of a comprehensive risk-management program for prescription opioid analgesics: Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS<sup>®</sup>). *Pain Medicine*. 2007;8(2):157-170.

Cicero TJ, Inciardi JA, Surratt HL. Trends in the use and abuse of branded and generic extended release oxycodone and fentanyl products in the United States. *Drug and Alcohol Dependence*. 2007;91:115-120.

Cicero TJ, Surratt HL, Inciardi JA, Munoz A. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban and urban locations in the United States. *Pharmacoepidemiol Drug Saf.* 2007;16:827-840.

Hughes AA, Bogdan GM, Dart RC, Reporting for the Researched Abuse Diversion and Addiction-Related Surveillance (RADARS<sup>®</sup>) System Poison Center Group. Active surveillance of abused and misused prescription opioids using poison center data: A pilot study and descriptive comparison. *Clinical Toxicology*. 2007;45:144-151.


Inciardi JA, Surratt HL, Lugo Y, Cicero TJ. The diversion of prescription opioid analgesics. *Law Enforcement Executive Forum Journal*. 2007;(November):127-141.

Rosenblum A, Parrino M, Schnoll SH, Fong C, Maxwell C, Cleland C, Magura S, Haddox D. Prescription opioid abuse among enrollees into methadone maintenance treatment. *Drug and Alcohol Dependence*. 2007;90:64-71.

Smith MY, Bailey JE, Woody GE, Kleber HD. Abuse of buprenorphine in the United States: 2003 – 2005. *Journal of Addictive Diseases*. 2007;26(3):107–111.

Smith MY, Schneider MF, Wentz A, Hughes A, Haddox JD, Dart RC. Quantifying morbidity associated with the abuse and misuse of opioid analgesics: A comparison of two approaches. *Clinical Toxicology*. 2007;456:23-30.

2006



Bailey JE, Barton PL, Lezotte D, Lowenstein SR, Dart RC. The effect of FDA approval of a generic competitor to OxyContin<sup>®</sup> (Oxycodone HCI Controlled-Release) tablets on the abuse of oxycodone. *Drug and Alcohol Dependence*. 2006;84:182-187.

Inciardi JA, Cicero TJ, Munoz A, Adams EH, Geller A, Senay EC, Woody GE. The diversion of Ultram<sup>®</sup>, Ultracet<sup>®</sup>, and generic tramadol HCI. *Journal of Addictive Diseases*. 2006;25:53-58.

Inciardi JA, Surratt HL, Kurtz SP, Burke JJ. The diversion of prescription drugs by health care workers in Cincinnati, Ohio. *Substance Use and Misuse.* 2006;41:255-264.

Smith MY, Dart RC, Hughes AA, Geller A, Senay EC, Woody GE, Colucci S. Clinician validation of poison control center intentional exposure cases involving prescription opioids. *American Journal of Drug and Alcohol Abuse*. 2006;32:465-478.


2005

Cicero TJ, Inciardi JA. Diversion and abuse of methadone prescribed for pain management. *Journal of the American Medical Association*. 2005;293(3):297-298.

Cicero TJ, Inciardi JA, Munoz A. Trends of abuse in OxyContin<sup>®</sup> and other opioid analgesics in the United States: 2002-2004. *The Journal of Pain*. 2005;6(10):662-672.

2003

Inciardi JA, Goode JL. OxyContin<sup>®</sup> and prescription drug abuse. *Consumers' Research.* 2003;86(7):17-21.



# **Abstracts & Presentations**

2019

#### American Association for the Treatment of Opioid Dependence

Severtson SG, Kreider SED, Goulding DF, Olsen H, Iwanicki JL, Ellis MS, Cicero TJ, McBride K, Dart RC. Changes in the prevalence of methamphetamine abuse among individuals entering medication-assisted treatment programs. American Association for the Treatment of Opioid Dependence National Conference. Orlando, FL. October 2019. **POSTER** 

### American College of Emergency Physicians

Schimmel J, Amioka E, Rockhill K, Haynes CM, Black JC, Dart RC, Iwanicki JL. Kratom use and high risk substance use behaviors in the United States non-medical use of prescription drugs national survey. American College of Emergency Physicians Scientific Assembly. Denver, CO. October 2019. **ORAL PRESENTATION** 

#### British Pharmacological Society

Dart RC. How can we determine the issues related to prescription medicine misuse and problems in the US? Pharmacology 2019. Edinburgh, UK. December 2019. SYMPOSIUM PRESENTATION

### Canadian Centre on Substance Abuse

Iwanicki JL, Black JC, May KP, Sproule B, Dart RC. Prevalence of non-medical use of prescription opioids in Canada in 2017. Canadian Centre on Substance Abuse Issues of Substance Conference. Ottawa, Ontario. November 2019. **POSTER** 

May KP, Schwarz J, Iwanicki JL. Cross-border trafficking of prescription oxycodone products manufactured in Canada. Ottawa, Ontario. November 2019. **POSTER** 

Severtson SG, Margolin ZR, Wogenstahl KW, Iwanicki JL, Levi-Minzi MA, Martin G, Buttram ME, Dart RC. Associations between legal and illegal distribution of prescription medications in Canada. Canadian Centre on Substance Abuse Issues of Substance Conference. Ottawa, Ontario. November 2019. **POSTER** 

#### Canadian Public Health Association: Public Health 2019

Nugent E, Black JC, Dart RC. Regional estimates for prevalence of non-medical use of prescription opioids in Canada. Canadian Public Health Association's Public Health 2019 Meeting. Ottawa, ON. April 2019. ORAL PRESENTATION

### **Canadian Society of Addiction Medicine**

Ellis MP. Diverging Epidemics: Shifting patterns of opioid use between treatment-seeking opioid users in Canada and the United States. Canadian Society of Addiction Medicine Annual Meeting and Scientific Conference, Halifax, Nova Scotia. October 2019. **ORAL PRESENTATION** 

# **Category 1 Focus Group Meeting**

Iwanicki JL. Real-world data: Do ADFs change behavior? What current opioid data imply for stimulants in the future. Category 1 Focus Group Meeting. Alexandria, VA. June 2019. INVITED PRESENTATION

# College on Problems of Drug Dependence

Asomaning K, Bau GE, Severtson SG, Rockhill K, Martire D, Dart RC. Abuse of pregabalin and gabapentin in the US. College on Problems of Drug Dependence Annual Meeting, San Antonio, TX. June 2019. **POSTER** 

Levi-Minzi MA, Margolin Z, Wogenstahl K, Martin G, Buttram ME, Kurtz SP. Examining prescription opioid diversion cases and cases involving illicitly manufactured opioids in Canada. College on Problems of Drug Dependence Annual Meeting, San Antonio, TX. June 2019. **POSTER** 



Severtson SG, Iwanicki JL, Kurtz SP, Dart RC. Misclassification bias may contribute to overestimates of use of specific opioid products. College on Problems of Drug Dependence Annual Meeting, San Antonio, TX. June 2019. **POSTER** 

Sproule B, Black JC, Dart RC. Non-medical use of codeine products in Canada. College on Problems of Drug Dependence Annual Meeting, San Antonio, TX. June 2019. **POSTER** 

### European Association of Poisons Centres and Clinical Toxicologists

Bonney CF, Iwanicki JL, Black JC, Haynes CM, Auriacombe M, Fonseca F, Guareschi M, Scherbaum N, Dart RC. Nonmedical use of prescription GABA analogues (gabapentin and pregabalin) in Europe in the Non-Medical Use of Prescription Drugs (NMURx) National Surveys. *Clin Toxicol.* 2019;57(6):568-569. **POSTER** 

Hockenhull J, Amioka E, Black JC, Haynes CM, Wood DM, Dart RC, Dargan PI. Differences in the pattern and prevalence of non-medical use of prescription benzodiazepines, gamma-aminobutyric acid (GABA) analogues and stimulants in Europe. *Clin Toxicol.* 2019;57(6):435. **POSTER** 

Hockenhull J, Wood DM, Haynes CM, Black JC, Rockhill K, Dart RC, Dargan PI. Regional variation in non-medical use of benzodiazepines in the UK. *Clin Toxicol.* 2019;57(6):434-435. **POSTER** 

Iwanicki JL, Haynes CM, Black JC, Auriacombe M, Dargan PI, Fonseca F, Guareschi M, Scherbaum N, Wood DM, Dart RC. Non-medical use of prescription stimulants in Europe in the Non-Medical Use of Prescription Drugs (NMURx) National Surveys. *Clin Toxicol.* 2019;57(6):441-442. **POSTER** 

LeRoy SJ, Margolin ZR, Lagrotteria JJ, Severtson SG, Mégarbane B, Villa A, Sesana F, Iwanicki JL, Dart RC. Regional variability in intentional exposures to prescription medications in France and Italy. *Clin Toxicol.* 2019;57(6):451-452. **POSTER** 

Severtson SG, Lagrotteria JJ, Margolin ZR, LeRoy SJ, Villa A, Schaper A, Ebbecke M, Sesana F, Mégarbane B, Iwanicki JL, Dart RC. Pediatric, self-harm cases comprise a large proportion of intentional exposures to methylphenidate reported to participating poison centres. *Clin Toxicol.* 2019;57(6):547-548. **POSTER** 

#### International Conference on Opioids

Dart RC. Data for the opioid crisis. International Conference on Opioids. Boston, MA. June 2019. SYMPOSIUM PRESENTATION

# Joint Statistical Meetings


Amioka EC, Black JC, Forber A, Rockhill KM, Dart RC. Methods for identifying careless responses in online survey data. Joint Statistical Meetings' 2019 Annual Meeting. Denver, CO. July 2019. **POSTER** 

Black JC, Forber A, Rockhill KM, Amioka EC, May KM, Dart RC. Method for selecting calibration weights in a nonprobability epidemiological survey. Joint Statistical Meetings' 2019 Annual Meeting. Denver, CO. July 2019. **POSTER** 

Kreider S. Report building: SAS and Microsoft Word VBA made easy. Joint Statistical Meetings' 2019 Annual Meeting. Denver, CO. July 2019. **ORAL PRESENTATION** 

Margolin ZR, Wogenstahl KW, Black JC, Olson RA, Dart RC. Utilizing the internet as a public health surveillance medium: outcomes from the RADARS<sup>®</sup> System Web Monitoring Program. Joint Statistical Meetings' 2019 Annual Meeting. Denver, CO. July 2019. **POSTER** 

Lisbon Addictions: European Conference on Addictive Behaviours and Dependencies



Dart RC. The mosaic approach to post-marketing surveillance. Lisbon Addictions 2019. Lisbon, Portugal. October 2019. SYMPOSIUM PRESENTATION

Iwanicki JL. Prescription drug misuse in France and Italy. Lisbon Addictions 2019. Lisbon, Portugal. October 2019. SYMPOSIUM PRESENTATION

Iwanicki JL. Principles and strategies for post-marketing surveillance of prescription drugs. Lisbon Addictions 2019. Lisbon, Portugal. October 2019. SYMPOSIUM PRESENTATION

Schwarz J. Better methods: novel methods and analyses to better understand prescription drug misuse. Lisbon Addictions 2019. Lisbon, Portugal. October 2019. SYMPOSIUM PRESENTATION

Schwarz J. Prescription drug misuse in Germany. Lisbon Addictions 2019. Lisbon, Portugal. October 2019. SYMPOSIUM PRESENTATION

Torrens M. Prescription drug misuse in Spain. Lisbon Addictions 2019. Lisbon, Portugal. October 2019. SYMPOSIUM PRESENTATION

Torrens M. Prescription opioid misuse in Europe: past, present and future. Lisbon Addictions 2019. Lisbon, Portugal. October 2019. SYMPOSIUM PRESENTATION

Wood DM. The future of prescription drug abuse beyond opioids: a U.K. perspective. Lisbon Addictions 2019. Lisbon, Portugal. October 2019. SYMPOSIUM PRESENTATION

Wood DM. Prescription drug misuse in the U.K. Lisbon Addictions 2019. Lisbon, Portugal. October 2019. SYMPOSIUM PRESENTATION

#### Military Health System Research Symposium

Iwanicki JL, Magtanong R, Amioka E, May KP, Black JC, Flarity K, Dart RC. Pilot of a novel online survey to assess riskbenefit profile of pain treatments. Military Health System Research Symposium. Kissimmee, FL. August 2019. **POSTER** 

#### North American Congress of Clinical Toxicology

Iwanicki JI, Black JC, Haynes CM, Dart RC. Cannabis use and high risk substance use behaviors in the United States non-medical use of prescription drugs (NMURx) national survey. *Clin Toxicol*. 2019; 57(10):1010-1011. **POSTER** 

Seidel Halmo L, Rockhill K, Black JC, Iwanicki JI. Prevalence of illicit drug and non-medical prescription drug use among pregnant women in the United States. *Clin Toxicol*. 2019; 57(10):1006-1007. **POSTER** 

### National Association for Public Health Statistics and Information Systems

Black JC, McCoy RH. Analysis of Drug Mentions with Involvement for prescription stimulants. National Association for Public Health Statistics and Information Systems' 2019 Annual Meeting. Columbus, OH. June 2019. ORAL PRESENTATION

#### PAINWeek

Black JC, Margolin ZR, Iwanicki JL, Dart RC. Perception of XTAMPZA<sup>®</sup> ER and other abuse-deterrent opioid formulations on the internet. PAINWeek 2019. Las Vegas, NV. September 2019. POSTER

Severtson SG, Wogenstahl K, Buttram ME, Kurtz S, Iwanicki JL, Dart RC. The diversion and street price of XTAMPZA<sup>®</sup> ER relative to other prescription opioids. PAINWeek 2019. Las Vegas, NV. September 2019. POSTER



Severtson SG, Wogenstahl K, Cicero TJ, Iwanicki JL, Dart RC. Abuse of XTAMPZA<sup>®</sup> ER is rare relative to other opioid analgesics. PAINWeek 2019. Las Vegas, NV. September 2019. **POSTER** 

#### 2018

#### American Academy of Addiction Psychiatry

Swanson JD, Black JC, Haynes CM, Rockhill K, May KP, Amioka E, Dart RC. Hierarchical clustering of mental health disorder diagnoses based on opioid non-medical use frequency. American Academy of Addiction Psychiatry Annual Meeting. Bonita Springs, FL. December 2018. **POSTER** 

#### American Association for the Treatment of Opioid Dependence

Fong C, Rosenblum A. Increase in drug injectors in Southeast U.S. and in rural-suburban counties among entrants to opioid treatment programs. American Association for the Treatment of Opioid Dependence National Conference. New York City, NY. March 2018. **POSTER** 

McBride K, Olsen H, Hill D, Ratcliffe K, D'Agnone O, Auriacombe M, Daulouède JP, Villèger P, Benyamina A, Touzeau D, Guareschi M, Iwanicki J, Green JL, Dart RC, Maremmani I. Reported chronic pain and overdose by patients enrolling in opioid dependence treatment in France and the United Kingdom. American Association for the Treatment of Opioid Dependence National Conference. New York City, NY. March 2018. **POSTER** 

Olsen H, McBride K, Hill D, Ratcliffe K, D'Agnone O, Auriacombe M, Daulouède JP, Villèger P, Benyamina A, Touzeau D, Guareschi M, Iwanicki J, Green JL, Dart RC, Maremmani I. Use of treatment history to identify drug differences in patients entering medication-assisted maintenance substance abuse treatment programs in France and the United Kingdom. American Association for the Treatment of Opioid Dependence National Conference. New York City, NY. March 2018. **POSTER** 

#### American Public Health Association

Rockhill K, Bau GE, Ellis MS, Cicero TJ, Dart RC. Mosaic approach for monitoring Healthy People 2020 objectives: A substance abuse surveillance system. American Public Health Association Annual Meeting. San Diego, CA. November 2018. **ORAL PRESENTATION** 

#### **Canadian Society of Addiction Medicine**

Ellis MP, Kasper ZA, Cicero TJ. Regional variations in opioid use patterns among treatment-seeking opioid users in Central and Western Canada. Canadian Society of Addiction Medicine Annual Meeting and Scientific Conference, Vancouver, British Columbia. October 2018. **POSTER** 


# Council of State and Territorial Epidemiologists

Rockhill K, May KP, Haynes C, Amioka E, Black JC, Dart RC. Evaluating surveillance indicators of prescription and illicit drug use using the RADARS<sup>®</sup> System Survey of Non-Medical Use of Prescription Drugs Program. Council of State and Territorial Epidemiologists Annual Conference, West Palm Beach, FL. June 2018. **ORAL PRESENTATION** 

### College on Problems of Drug Dependence

Buttram M, Kurtz SP. Law enforcement reports of increasing methamphetamine use and associations with the opioid epidemic. College on Problems of Drug Dependence Annual Meeting, San Diego, CA. June 2018. **POSTER** 

Ellis MS, Kasper ZA, Cicero TJ. Substantial increases in methamphetamine use among a national sample of treatmentseeking opioid users. College on Problems of Drug Dependence Annual Meeting, San Diego, CA. June 2018. **ORAL PRESENTATION** 



Olsen HA, Severtson SG, Schwarz J, Ellis M, Cicero TJ, Dart RC. Comparing prescription opioids, methadone, and heroin rates from the Treatment Episode Data Set to the RADARS<sup>®</sup> System Treatment Center Programs. College on Problems of Drug Dependence Annual Meeting, San Diego, CA. June 2018. **POSTER** 

Iwanicki J, Hennessy M, Severtson SG, McBride K, Schwarz J, Scherbaum N, Hill D, Guareschi M, Dart RC, Maremmani I. Gabapentin and pregabalin abuse among EUROPAD subjects. National Institute on Drug Abuse (NIDA) International Forum at College on Problems of Drug Dependence Annual Meeting, San Diego, CA. June 2018. **POSTER** 

Torrens M, Fonseca F, Farré M, McBride K, Maremmani I, Guareschi M, Dart RC. Benzodiazepines use "to get high" in patients admitted for addiction treatment in Spain. College on Problems of Drug Dependence Annual Meeting, San Diego, CA. June 2018. **POSTER** 

Cross Company Abuse Liability Council's Advancements and Challenges in Abuse Potential Evaluation Iwanicki JL. Innovative approaches to post-marketing surveillance. Cross Company Abuse Liability Council's Advancements and Challenges in Abuse Potential Evaluation Conference. Bethesda, MD. October 2018. INVITED PRESENTATION

#### EUROPAD

Olsen HA, Severtson SG, McBride K, Kern C, Guareschi M, Hill D, D'Agnone O, Ratcliffe K, Auriacombe M, Daulouède JP, Villèger P, Touzeau D, Benyamina A, Scherbaum N, Deruvo G, Clausen T, Fonseca MF, Bacciardi S, Iwanicki J, Dart RC, Maremmani I. Comparing prescription opioid use among heroin abusers using the RADARS<sup>®</sup> System EUROPAD Program. 13<sup>th</sup> European Opiate Addiction Treatment Association Conference. Krakow, Poland. May 2018. **POSTER** 

#### European Association of Poisons Centres and Clinical Toxicologists

Fischer LJ, Severtson SG, LeRoy SJ, Margolin ZR, Green JL, Mégarbane B, Villa A, Schaper A, Ebbecke M, Sesana F, and Radars® System Poison Center Group. Intentional opioid exposures with benzodiazepine co-ingestants in the US and Europe as reported to the RADARS<sup>®</sup> System Global Toxicosurveillance Network. *Clin Toxicol.* 2018;56(6):472. **POSTER** 

Margolin ZR, Severtson SG, LeRoy SJ, Fischer LJ, Green JL, Mégarbane B, Villa A, Schaper A, Ebbecke M, Sesana F, Thomas SHL, Thompson JP. Unintentional pediatric exposures to prescription medications in Europe as reported to the RADARS<sup>®</sup> System Global Toxicosurveillance Network. *Clin Toxicol.* 2018;56(6):550. **POSTER** 

#### Human Abuse Liability Testing & Market Access Conference

Nugent E. Better understand opioids with low market share. Human Abuse Liability Testing & Market Access Conference. Herndon, VA. November 2018. INVITED PRESENTATION

#### International Society of Addiction Medicine

Kurtz SP, Buttram ME, Margolin ZR, Wogenstahl K. The diversion of non-scheduled psychoactive prescription drugs in the United States. 20<sup>th</sup> International Society of Addiction Medicine Annual Meeting. Busan, South Korea. November 2018. ORAL PRESENTATION

#### North American Congress of Clinical Toxicology

Hockenhull J, Amioka E, Black JC, Haynes CM, Wood DM, Dart RC, Dargan PI. Alprazolam misuse among young people in the United Kingdom. *Clin Toxicol.* 2018; 56(10):972-973. **POSTER** 

Iwanicki JL, Hennessy M, Severtson SG, McBride KE, Schwarz J, Scherbaum N, Hill D, Guareschi M, Dart RC, Maremanni I. Gabapentinoid abuse among EUROPAD subjects. *Clin Toxicol*. 2018; 56(10):974. **POSTER** 

#### PAINWeek



Iwanicki JL, Magtanong R, Black J, Dart RC. Content validity of a survey to evaluate the benefits and risks associated with treatments for pain. PAINWeek 2018. Las Vegas, NV. September 2018. **POSTER** 

Iwanicki JL, Vosburg SK, Severtson SG, Dart RC, Cicero TJ, Kurtz SP, Parrino MW, Green JL. Assessment of tapentadol API abuse liability with the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS<sup>®</sup>) System Poison Center Program. PAINWeek 2018. Las Vegas, NV. September 2018. **POSTER** 

### Society for Epidemiologic Research

Dasgupta N, Schwarz J, Dart RC. Trend-in-trend method to analyze abuse of new and low volume opioids in the community setting. Society for Epidemiologic Research 51<sup>st</sup> Annual Meeting. Baltimore, MD. June 2018. **POSTER** 

2017

#### Association for Medical Education and Research in Substance Abuse

Dart RC. The myths and realities of the opioid epidemic. Association for Medical Education and Research in Substance Abuse Annual Meeting. Washington, DC. November 2017. **SYMPOSIUM PRESENTATION** 

Dasgupta N. Challenging my illusions about the opioid crisis. Association for Medical Education and Research in Substance Abuse Annual Meeting. Washington, DC. November 2017. SYMPOSIUM PRESENTATION

### **Canadian Centre on Substance Abuse**

Iwanicki JL, Haynes CM, Sproule B, Kurtz SP, Cicero TJ, Dasgupta N, Dart RC, Green JL. Five program system for postmarketing surveillance of prescription drug misuse. Canadian Centre on Substance Abuse Issues of Substance Conference. Calgary, Alberta. November 2017. **POSTER** 

Levi-Minzi MA, Martin G, Kurtz SP, Dziadkowiec O, Le Lait MC, Margolin Z, Rosen T, Green JL, Dart RC. The opioid epidemic in Canada: trends in diversion of commonly abused prescription drugs in Canada. Canadian Centre on Substance Abuse Issues of Substance Conference. Calgary, Alberta. November 2017. **POSTER** 

#### **Canadian Pain Society**

May KP, Rosen T, Dasgupta N, Green JL, Dart RC. Cross-border trafficking of prescription oxycodone products manufactured in Canada. Canadian Pain Society 38<sup>th</sup> Annual Scientific Meeting. Halifax, NS. May 2017. **POSTER** 

Severtson SG, Kreider S, Bucher Bartelson B, Ellis MS, Cicero TJ, Green JL, Dart RC. C Past month prevalence of chewing, snorting, smoking and injecting prescription opioid tablets and capsules among individuals entering substance abuse treatment. Canadian Pain Society 38<sup>th</sup> Annual Scientific Meeting. Halifax, NS. May 2017. **POSTER** 


#### **Canadian Society of Addiction Medicine**

May KP, Rockhill KM, Eldred-Skemp NA, Haynes CM, Sproule B, Dart RC, Green JL. Non-medical use and abuse of drugs used for opioid agonist therapy in Canada. Canadian Society of Addiction Medicine Annual Meeting and Scientific Conference, Niagara Falls, Ontario. October 2017. **POSTER** 

May KP, Rockhill KM, Sproule B, Eldred-Skemp NA, Haynes CM, Dart RC, Green JL. Prevalence of non-medical use of prescription drugs in Canada. Canadian Society of Addiction Medicine Annual Meeting and Scientific Conference, Niagara Falls, Ontario. October 2017. **POSTER** 

McBride K, Olsen H, Cicero TJ, Green JL, Iwanicki J, Dart RC. Reported chronic pain and overdose by patients enrolling in opioid dependence treatment. Canadian Society of Addiction Medicine Annual Meeting and Scientific Conference, Niagara Falls, Ontario. October 2017. **POSTER** 

#### College on Problems of Drug Dependence



Dart RC. Interventions in prescription opioid abuse – do (or can) prescription monitoring programs make a difference? College on Problems of Drug Dependence Annual Meeting, Montreal, Quebec. June 2017. **INVITED PRESENTATION** 

Dziadkowiec O, LeLait MC, Margolin ZR, Rosen T, Green JL, Dart RC, Kurtz SP. The opioid epidemic in Canada: trends in diversion of commonly abused prescription drugs in Ontario. National Institute on Drug Abuse (NIDA) International Forum at College on Problems of Drug Dependence Annual Meeting, Montreal, Quebec. June 2017. **POSTER** 

Fonseca F, Torrens M, Farré M, McBride KE, Maremmani I, Guareschi M, Green JL, Dart RC. Patterns of cannabis use in patients admitted for addiction treatment in Spain. National Institute on Drug Abuse (NIDA) International Forum at College on Problems of Drug Dependence Annual Meeting, Montreal, Quebec. June 2017. **POSTER** 

Kurtz SP, Buttram ME. Systematic surveillance of illicitly manufactured fentanyl cases initiated by law enforcement. College on Problems of Drug Dependence Annual Meeting, Montreal, Quebec. June 2017. ORAL PRESENTATION

May KP, Haynes CM, Rockhill KM, Margolin ZR, Dart RC, Green JL. Prevalence of non-medical use of prescription drugs in the United States in 2016. College on Problems of Drug Dependence Annual Meeting, Montreal, Quebec. June 2017. **POSTER** 

Rockhill KM, Haynes CM, May KP, Margolin ZR, Dart RC, Green JL. Prevalence of illicit drug use: Survey of Non-Medical Use of Prescription Drugs Program compared to NSDUH. College on Problems of Drug Dependence Annual Meeting, Montreal, Quebec. June 2017. **POSTER** 

Rosen T, Margolin ZR, LeLait MC, Dziadkowiec O, Green JL, Dart RC, Kurtz SP. The Great Lakes effect: discovering hot spots for rates of diversion of prescription opioids within Ontario, Canada. National Institute on Drug Abuse (NIDA) International Forum at College on Problems of Drug Dependence Annual Meeting, Montreal, Quebec. June 2017. **POSTER** 

Rosenblum A, Pouget E, Fong C. Racial/ethnic trends of heroin and non-medical use of prescription opioids among entrants to opioid treatment programs, 2005-2016. College on Problems of Drug Dependence Annual Meeting, Montreal, Quebec. June 2017. **POSTER** 

#### **European Association of Poisons Centres and Clinical Toxicologists**

Chan WL, Wood DM, Haynes CM, Rockhill KM, Green JL, Dargan PI. An online survey on misuse of benzodiazepines and 'Z drugs' in Singapore. *Clin Toxicol.* 2017;55(5):441-442. **POSTER** 

Dargan PI, Haynes CM, Wood DM, May KP, Rockhill KM, Green JL. Non-medical use of loperamide in the United Kingdom. *Clin Toxicol.* 2017;55(5):449. **POSTER** 

Fischer LJ, Margolin ZR, Green JL, Mégarbane B, Villa A, Schaper A, Ebbecke M, Sesana F, Thomas S, Thompson J. Age of Misuse Exposures Reported by the Global Toxicosurveillance Network (GTNet). *Clin Toxicol.* 2017;55(5):426. ORAL PRESENTATION

Iwanicki JL, Margolin ZR, Severtson SG, Dart RC. Relationship between poison center opioid exposure and mortality rates and National Vital Statistics System mortality rates. *Clin Toxicol.* 2017;55(5):475. **ORAL PRESENTATION** 

Wood DM, Green JL, Haynes CM, Rockhill KM, Dargan PI. Comparison of prevalence of illicit drug use in the UK Survey of Non-Medical Use of Prescription Drugs Program and the annual Crime Survey for England and Wales between 2014 and 2016. *Clin Toxicol.* 2017;55(5):445-446. **POSTER** 

#### EUROTOX



Green JL. Trends in opioid analgesic abuse and mortality in Europe in 2017. 53<sup>rd</sup> Congress of the European Societies of Toxicology. Bratislava, Slovakia. September 2017. SYMPOSIUM PRESENTATION

#### Human Abuse Liability & Abuse Deterrent Formulations Conference

Iwanicki JL. Spotlight: New prescription drugs of abuse and their opioid interaction risks. Human Abuse Liability & Abuse Deterrent Formulations Conference. Bethesda, MD. November 2017. INVITED PRESENTATION

### International Conference on Opioids

Dart RC. Effect of abuse-deterrent formulations and immediate-release opioids on abuse, overdose and death from Rx opioids. International Conference on Opioids. Boston, MA. June 2017. SYMPOSIUM PRESENTATION

Severtson SG, Vosburg SK, Green JL, Dart RC. Rate of Nucynta® ER intentional abuse calls to poison centers are lower than ER oxycodone and ER oxymorphone. International Conference on Opioids. Boston, MA. June 2017. **POSTER** 

Vosburg SK, Severtson SG, Green JL, Kurtz SP, Dart RC. Abuse liability of tapentadol is significantly lower than other schedule II opioids. International Conference on Opioids. Boston, MA. June 2017. **POSTER** 

### International Conference on Pharmacoepidemiology & Therapeutic Risk Management

Dart RC. What have we learned about the impact of policies in North America? International Conference on Pharmacoepidemiology & Therapeutic Risk Management Annual Meeting. Montreal, Quebec. August 2017. SYMPOSIUM PRESENTATION

Dasgupta N, Schwarz J, Dart RC. Case review of opioid-induced thrombotic thrombocytopenic purpura (TTP) from pharmacovigilance and poison centers. *Pharmacoepidemiol Drug Saf.* 2017; 26(Suppl 2):634-635. **POSTER** 

#### Lisbon Addictions: European Conference on Addictive Behaviours and Dependencies

Dart RC. The evolution of the opioid abuse epidemic in North America. Lisbon Addictions 2017. Lisbon, Portugal. October 2017. SYMPOSIUM PRESENTATION

Green JL. The European experience: prescription drug misuse in France, Germany, Italy and Spain. Lisbon Addictions 2017. Lisbon, Portugal. October 2017. SYMPOSIUM PRESENTATION

Wood DM. The landscape of prescription drug misuse in the UK. Lisbon Addictions 2017. Lisbon, Portugal. October 2017. SYMPOSIUM PRESENTATION

#### North American Congress of Clinical Toxicology

Benallo MA, Kreider SE, Green JL, Dart RC. Comparing intentional exposure rates between stimulants in the RADARS<sup>®</sup> System poison center data. *Clin Toxicol*. 2017; 55(7):761. **POSTER** 

#### PAINWeek

Haynes CM, Rockhill KM, May KP, Black JC, Dart RC, Green JL. Increased risk of problematic drug use among adults with chronic pain. PAINWeek 2017. Las Vegas, NV. September 2017. POSTER

Severtson SG, Vosburg SK, Green JL, Dart RC. Rate of Nucynta® ER intentional abuse calls to poison centers are lower than ER oxycodone and ER oxymorphone. PAINWeek 2017. Las Vegas, NV. September 2017. POSTER

#### Saudi Psychiatric Association

Dart RC. Potential solutions to epidemic substance abuse in US and Europe. Saudi Psychiatric Association Meeting. Riyadh, Saudi Arabia. October 2017. INVITED PRESENTATION



Dart RC. Substance abuse in US and Europe. Saudi Psychiatric Association Meeting. Riyadh, Saudi Arabia. October 2017. INVITED PRESENTATION

#### 2016

#### American Academy of Pain Medicine

Dart RC. The changing landscape of prescription opioid abuse in the United States. 32<sup>nd</sup> American Academy of Pain Medicine Annual Meeting. Palm Springs, CA. February 2016. **INVITED PRESENTATION** 

#### American Association of Pharmaceutical Scientists

Dart RC. The evolution of abuse deterrent drug formulations: Testing effectiveness from the benchtop to the real world. American Association of Pharmaceutical Scientists Annual Meeting. Denver, CO. November 2016. SYMPOSIUM PRESENTATION

#### American Association for the Treatment of Opioid Dependence

Bau G, Goodman E, McBride K, Guareschi M, Hill D, D'Agnone O, Auriacombe M, Daulouède JP, Villèger P, Touzeau D, Benyamina A, Scherbaum N, Deruvo G, Clausen T, Fonseca F, Bacciardi S, Green JL, Dart RC, Maremmani I. Characterizing opioid and benzodiazepine abuse as reported by patients entering medication-assisted substance abuse treatment programs in Europe. American Association for the Treatment of Opioid Dependence National Conference. Baltimore, MD. October 2016. **POSTER** 

McDaniel HA, Goodman E, McBride K, Green JL, Rosenblum A, Dart RC. Characterizing opioid and benzodiazepine abuse as reported to opioid treatment programs in the United States. American Association for the Treatment of Opioid Dependence National Conference. Baltimore, MD. October 2016. **POSTER** 

Pouget ER, Fong C, Rosenblum A. Racial/ethnic differences in primary drug used among entrants to opioid treatment programs over time. American Association for the Treatment of Opioid Dependence National Conference. Baltimore, MD. October 2016. **POSTER** 

#### American College of Medical Toxicology

Iwanicki JL, Le Lait MC, Severtson SG, Bucher-Bartelson B, Dart RC. Prescription Opioid Death Rates are Greater for Females than Males. American College of Medical Toxicology Annual Scientific Meeting. Huntington Beach, CA. March 2016. **POSTER** 

#### American Pain Society

Severtson SG, Bucher-Bartelson B, Green JL, Dart RC. Routes of administration of Tapentadol products as reported to poison centers. 35<sup>th</sup> Annual Scientific Meeting of the American Pain Society. Austin, TX. May 2016. **POSTER** 

#### American Public Health Association

Wang GS, Bau G, Severtson SG, Green JL, Dart RC. Impact of unit dose packaging on unintentional pediatric buprenorphine exposures. American Public Health Association Annual Meeting. Denver, CO. October 2016. **POSTER** 

#### College on Problems of Drug Dependence

Bucher-Bartelson B, Bau G, Severtson SG, Green JL, Dart RC. Increasing abuse of gabapentin and pregabalin as reported to US poison centers 2006 through 2014. College on Problems of Drug Dependence Annual Meeting, Palm Springs, CA. June 2016. **POSTER** 

DeVeaugh-Gess A, Chilcoat H, Coplan P, Harikishnan V, Besharat AC, Green JL. Monitoring internet postings for mentions of an extended-release (ER) hydrocodone formulation with abuse-deterrent properties. College on Problems of Drug Dependence Annual Meeting, Palm Springs, CA. June 2016. **POSTER** 



Fonseca F, Torrens M, Farré M, McBride KE, Maremmani I, Guareschi M, Touzeau D, Villeger P, Benyamina A, D'Agnone O, Somaini L, Dart RC. Patterns of prescription drug use and misuse in Spain: The European opioid treatment patient survey. National Institute on Drug Abuse (NIDA) International Forum at College on Problems of Drug Dependence Annual Meeting, Palm Springs, CA. June 2016. **POSTER** 

# EUROPAD

Green JL. RADARS System collaboration: European opioid treatment program goals and data. 12<sup>th</sup> European Opiate Addiction Treatment Association Conference. Leiden, Netherlands. May 2016. SYMPOSIUM PRESENTATION

Margolin ZR, Bau G, McBride KE, Guareschi M, Hill D, D'Agnone O, Auriacombe M, Daulouede JP, Villeger P, Touzeau D, Benyamina A, Scherbaum N, Deruvo G, Clausen T, Fonseca MF, Goodman E, Bacciardi S, Green JL, Dart RC, Maremmani I. A characterization of first-time enrollees and repeated enrollees entering medication-assisted substance abuse treatment programs. 12<sup>th</sup> European Opiate Addiction Treatment Association Conference. Leiden, Netherlands. May 2016. **POSTER** 

McBride KE, Guareschi M, Bau G, Margolin ZR, Hill D, D'Agnone O, Auriacombe M, Daulouede JP, Villeger P, Touzeau D, Benyamina A, Scherbaum N, Deruvo G, Clausen T, Fonseca MF, Bacciardi S, Goodman E, Green JL, Dart RC, Maremmani I. Reported route and source of primary drugs of abuse by patients entering medication-assisted substance abuse treatment in Europe. 12<sup>th</sup> European Opiate Addiction Treatment Association Conference. Leiden, Netherlands. May 2016. **POSTER** 

#### European Association of Poisons Centres and Clinical Toxicologists

Chan WL, Wood DM, Besharat AC, McDaniel HA, Green JL, Dargan PI. Online survey on prescription medicine misuse: what is the evidence for prescription opioid misuse in Singapore? *Clin Toxicol.* 2016;54(4):402. **POSTER** 

Dart RC. Abuse Deterrent Formulations of the opioids and their relation to heroin. XXXVI Annual International Congress of the European Association of Poisons Centres and Clinical Toxicologists. Madrid, Spain, May 2016. SYMPOSIUM PRESENTATION

Green JL. Trends in opioid analgesic abuse and mortality in Europe. XXXVI Annual International Congress of the European Association of Poisons Centres and Clinical Toxicologists. Madrid, Spain, May 2016. INVITED PRESENTATION

Iwanicki JL, McDaniel HA, Severtson SG, Green JL, Dart RC. Abuse of immediate release opioid analgesics as compared to extended release formulations in the United States. *Clin Toxicol.* 2016;54(4):402. **ORAL PRESENTATION** 

Johnson DJG, Cooper G, Davanzo F, Ebbecke M, Eddelston M, Garnier R, Margolin ZR, Megarbane B, Schaper A, Sesana F, Thomas SHL, Thompson JP, Vale AJ, Green JL. Tracking the trends over time of global adult human exposures to benzodiazepines and opioids reported to poison centres in the Global Toxicosurveillance Network. *Clin Toxicol.* 2016;54(4):466. POSTER

Johnson DJG, Cooper G, Davanzo F, Ebbecke M, Eddelston M, Garnier R, Margolin ZR, Megarbane B, Schaper A, Sesana F, Thomas SHL, Thompson JP, Vale AJ, Green JL. Tracking the trends over time of unintentional pediatric exposures to benzodiazepines and opioids reported to poison centres in the Global Toxicosurveillance Network. *Clin Toxicol.* 2016;54(4):465. **POSTER** 

Wang GS, Besharat AC, Le Lait MC, Haynes C, Dart RC, Roosevelt G. Characterization of marijuana use in college students as reported to an online survey. *Clin Toxicol.* 2016;54(4):460. **POSTER** 



## **Global Addiction Conference**

Kurtz SP, Buttram ME. Intertwined Non-pharmaceutical Fentanyl Epidemics in Canada and the United States. Global Addiction Conference. Venice, Italy, October 2016. **POSTER** 

#### International Conference on Opioids

Dart RC. The evolution of abuse deterrent drug formulations: testing effectiveness from the benchtop to the real world. International Conference on Opioids. Boston, MA. June 2016. SYMPOSIUM PRESENTATION

#### National Academies of Sciences, Engineering, and Medicine

Cicero TJ. Post-Marketing Surveillance: Lessons Learned and Recommendations for the Future. National Academies of Sciences, Engineering, and Medicine's Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse. Washington, DC. November 2016. INVITED PRESENTATION

Dart RC. Opioid analgesics with abuse-deterrent properties: current data and future opportunities. National Academies of Sciences, Engineering, and Medicine's Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse. Washington, DC. September 2016. INVITED PRESENTATION

# North American Congress of Clinical Toxicology

Benallo M, McDaniel HA, Green JL, Dart RC, RADARS System Poison Center Group. Severe adverse events associated with intentional abuse via an unintended route for fentanyl patches compared to other schedule II opioids. *Clin Toxicol.* 2016;54(8):708. **POSTER** 

Fischer LJ, Severtson SG, Green JL, Dart RC, RADARS System Poison Center Group. Intentional abuse cases mentioning prescription opioid products following the hydrocodone rescheduling. *Clin Toxicol.* 2016;54(8):709-710. **POSTER** 

Johnson DJD, Cooper G, Davanzo F, De Vries I, Ebbecke M, Eddelston M, Garnier R, Kaiser G, Margolin ZR, Megarbane B, Schaper A, Sesana F, Surkus J, Thomas SHL, Thompson JP, Vale AJ, Green JL. International perspective on prescription benzodiazepine exposures reported by poison centres in the Global Toxicosurveillance Network. *Clin Toxicol.* 2016;54(8):702-703. **POSTER** 

Warrick BJ, Sycamore K, Holbrook BD, Smolinske S, Seifert SA, Bau G, Bucher Bartelson B, Severtson SG, Green JL, Dart RC. Prescription opioid abuse or misuse in pregnancy using poison center data. *Clin Toxicol.* 2016;54(8):718. **POSTER** 

#### PAINWeek

Green JL, Kreider SED, Severtson SG, Dart RC. Accidental unsupervised ingestions of Nucynta<sup>®</sup> ER in children less than six years-old: Frequency and risk of severe outcomes. PAINWeek 2016. Las Vegas, NV. September 2016. POSTER

Green JL, Le Lait MC, Severtson SG, Dart RC. Tampering and medical outcomes in poison center abuse and misuse Nucynta<sup>®</sup> ER exposures. PAINWeek 2016. Las Vegas, NV. September 2016. POSTER

#### Pediatric Academic Societies

Wang GS, McDaniel HA, Bucher Bartelson B, Green JL, Dart RC. Unintentional exposures to prescription opioid analgesics among children under age six: trends over time. Pediatric Academic Societies Meeting. Baltimore, MD. May 2016. **ORAL PRESENTATION** 

#### Society of General Internal Medicine

Calcaterra SL, Severtson SG, Bucher-Bartelson B, Bau GE, Margolin ZR, Green JL, Dart RC. Trends in benzodiazepine and opioid analgesic misuse and mortality reported to poison centers across the United States. Society of General Internal Medicine Annual Meeting. Hollywood, FL. May 2016. **POSTER** 



2015

#### American Academy of Addiction Psychiatry

Severtson SG, Bucher Bartelson B, McDaniel HA, Green JL, Besharat AC, Cicero T, Ellis M, Kurtz SP, Rosenblum A, Dart RC. Abuse and diversion of buprenorphine/naloxone oral film relative to other buprenorphine formulations. American Academy of Addiction Psychiatry Annual Meeting. Huntington Beach, CA. December 2015. **POSTER** 

Severtson SG, Bucher Bartelson B, McDaniel HA, Green JL, Besharat AC, Dart RC. Unintentional exposures to buprenorphine/naloxone tablets and oral film among children less than six years old; October 2010 through June 2015. American Academy of Addiction Psychiatry Annual Meeting. Huntington Beach, CA. December 2015. **POSTER** 

#### American Association for the Treatment of Opioid Dependence

Fong C, Rosenblum A. Reductions in prescription opioid abuse among enrollees into opioid treatment programs. American Association for the Treatment of Opioid Dependence National Conference. Atlanta, GA. March 2015. **POSTER** 

Green JL. Emerging trends in alternative routes reported for prescription drug misuse: an international perspective. American Association for the Treatment of Opioid Dependence National Conference. Atlanta, GA. March 2015. **INVITED PRESENTATION** 

Lavery SA, Martinez EM, Bucher Bartelson B, Guareschi M, Touzeau D, Walcher S, Deruvo G, Somaini L, Fonseca F, McBride KE, Green JL, Maremmani I, Rosenblum A, Parrino M, Cicero TJ, Dart RC. Age and gender distribution among patients entering treatment for opioid addiction. American Association for the Treatment of Opioid Dependence National Conference. Atlanta, GA. March 2015. **POSTER** 

Somaini L, Maremmani I, Martinez EM, Fonseca F, Touzeau D, Guareschi M, Deruvo G, Walcher S, Bucher Bartelson B, Green JL, McBride KE, Rosenblum A, Parrino M, Dart RC. Use of opiates to get high in patients seeking opiate addiction treatment: Europe and the U.S. American Association for the Treatment of Opioid Dependence National Conference. Atlanta, GA. March 2015. **POSTER** 

#### Asia Pacific Association of Medical Toxicology

Chan WL, Wood DM, Besharat AC, McDaniel HA, Green JL, Dargan PI. Online survey on prescription medicine misuse: what is the evidence for misuse of benzodiazepines and 'Z drugs' in Singapore? Asia Pacific Association of Medical Toxicology 14<sup>th</sup> International Scientific Conference. Perth, Australia. December 2015. **ORAL PRESENTATION** 

#### **Canadian Centre on Substance Abuse**

Dart RC, Goodman EM, McBride K, Margolin Z, Dasgupta N, Menone C, Green JL, Iwanicki JL. Monitoring the Street Price of Diverted Opioids in Canada with StreetRx.com. Canadian Centre on Substance Abuse Issues of Substance Conference. Montreal, Quebec. November 2015. **POSTER** 

Iwanicki JL, Besharat AC, Goodman EM, Dargan PI, Wood DM, Dart RC, Green JL. Chronic Pain and Non-Medical Use of Prescription Opioids in a United Kingdom National Survey. Canadian Centre on Substance Abuse Issues of Substance Conference. Montreal, Quebec. November 2015. **POSTER** 

#### **Canadian Pain Society**

Austin E, Thompson M, Hudson H, Bernabeo D, Johnson DJG, Dart RC. Trends in Tramadol Use and Abuse reported to the Ontario Poison Centre. Canadian Pain Society 36<sup>th</sup> Annual Scientific Meeting. Charlottetown, PEI. May 2015. **POSTER** 



Severtson SG, Besharat AC, Green JL, Dasgupta N, Ellis MS, Cicero TJ, Dart RC. Transborder trafficking of prescription opioids in Canada and the United States. Canadian Pain Society 36<sup>th</sup> Annual Scientific Meeting. Charlottetown, PEI. May 2015. **POSTER** 

#### College on Problems of Drug Dependence

Green JL, Dargan PI, Wood DM, Besharat AC, Martinez EM, Dart RC. An online national survey and the Crime Survey for England and Wales: are the data comparable? College on Problems of Drug Dependence Annual Meeting, Phoenix, AZ. June 2015. **POSTER** 

Iwanicki JL, Le Lait MC, Severtson SG, Bucher-Bartelson B, Dart RC. Prescription opioid death rates are greater for females than males. College on Problems of Drug Dependence Annual Meeting, Phoenix, AZ. June 2015. **ORAL PRESENTATION** 

McRae EM, Le Lait MC, West N, Dart RC. A comparison of attempted suicide rates by methylphenidate exposure in adult and adolescent populations. College on Problems of Drug Dependence Annual Meeting, Phoenix, AZ. June 2015. **ORAL PRESENTATION** 

Rosenblum A, Fong C, Matusow H, Parrino M, Maxwell-Taylor C. Reductions in prescription opioid abuse among enrollees into opioid treatment programs. College on Problems of Drug Dependence Annual Meeting, Phoenix, AZ. June 2015. **ORAL PRESENTATION** 

#### Community Anti-Drug Coalitions of America

Dart RC. Innovations in Rx technology: a session on abuse deterrent formulations. Community Anti-Drug Coalitions of America National Leadership Forum. National Harbor, MD. February 2015. INVITED PRESENTATION

#### Cross-Company Abuse Liability Council's Advancements in Abuse Potential Assessments

Dasgupta N. Crowdsourcing as a way to evaluate drug abuse in the community. Cross-Company Abuse Liability Council's Advancements in Abuse Potential Assessments – Building on the FDA Draft Guidance for Industry. Bethesda, MD. April 2015. INVITED PRESENTATION

#### European Association of Poisons Centres and Clinical Toxicologists

Bucher Bartelson B, Desel H, Schaper A, Davanzo F, Sesana F, Cooper G, Thompson JP, Johnson DJG, Green JL. Trends Over Time in Population Rates of Intentional Misuse and Self-Harm Mentions with Buprenorphine, Methadone, and Oxycodone as Reported to Poison Centres in Germany, Italy, and the United Kingdom. *Clin Toxicol.* 2015;53(4):374. **ORAL PRESENTATION; POSTER** 

Dargan PI, Martinez EM, Besharat AC, Green JL, Wood DM. Prescription Opioids: Reported Reasons for Non-Medical Use in an Online National Survey in the UK. *Clin Toxicol.* 2015;53(4):375-376. **POSTER** 

Dargan PI, Wood DM, Besharat AC, Martinez EM, Green JL. Chronic Pain and Non-Medical Use of Opioids, Benzodiazepines, and Pregabalin in an Online National Survey in the United Kingdom. *Clin Toxicol.* 2015;53(4):377. ORAL PRESENTATION; POSTER

Wood DM, Besharat AC, Dargan PI, Martinez EM, Green JL. Pregabalin, Gabapentin and Baclofen: Sources of Drug Acquisition for Non-Medical Use in an Online National Survey in the UK. *Clin Toxicol.* 2015;53(4):376-377. **POSTER** 

Wood DM, Besharat AC, Martinez EM, Green JL, Dargan PI. Benzodiazepines and 'Z Drugs': Reported Reasons for Non-Medical Use in an Online National Survey in the UK. *Clin Toxicol.* 2015;53(4):377-378. **POSTER** 

Wood DM, Dargan PI, Besharat AC, Martinez EM, Green JL. Perception of Prescription Drug Safety in an Online National Survey in the United Kingdom. *Clin Toxicol.* 2015;53(4):369-370. **POSTER** 



## International Conference on Pharmacoepidemiology & Therapeutic Risk Management

Green JL, Besharat AC, Goodman EM, Bucher Bartelson B, Wood DM, Dargan PI. Non-Medical Use of Benzodiazepines and Opioids: an Online National Survey in the United Kingdom. *Pharmacoepidemiol Drug Saf.* 2015; 24:377-378. **POSTER** 

#### International Society of Addiction Medicine

Iwanicki JL. "Falling rates of prescription opioid abuse and death in the United States: Formulations and ramifications." 17th International Society of Addiction Medicine Annual Meeting. Dundee, Scotland, October 2015. SYMPOSIUM PRESENTATION

#### North American Congress of Clinical Toxicology

Fischer LJ, Severtson SG, Dart RC, RADARS System Poison Center Group. Prevalence of Serious Adverse Events by Injection or Inhalation of Prescription Stimulants. *Clin Toxicol.* 2015;53(7):660-661. **POSTER** 

Fix CM, Besharat AC, Dart RC. Characterization of Chronic Pain in College Students as Reported to an Online Survey. *Clin Toxicol.* 2015;53(7):758. **POSTER** 

Lavery SA, Le Lait MC, West NA, Dart RC, RADARS System Poison Center Group. Rates of Suicide Involving Prescription Opioids Before, During and After the Great Recession. *Clin Toxicol.* 2015;53(7):727-728. **POSTER** 

Lavery SA, West NA, Le Lait MC, Dart RC, RADARS System Poison Center Group. Trends of suspected suicide involving prescription opioids by 4 United States regions. *Clin Toxicol.* 2015;53(7):646. **ORAL PRESENTATION** 

Margolin Z, Besharat AC, Nelson SK, West NA, Bucher Bartelson B, Green JL, Dart RC. Non-medical Use of Prescription and Illicit Drugs in Public versus Private Colleges & Universities. *Clin Toxicol.* 2015;53(7):731. **POSTER** 

Marquess SA, McDaniel HA, West NA, Dart RC, RADARS System Poison Center Group. Decrease in Exposure Calls to Poison Centers: A Look at Opioid and Stimulant Drug Classes Over time By Age Group. *Clin Toxicol.* 2015;53(7):722-723. **POSTER** 

Nickless JR, Le Lait MC, West NA, Coulter MS, Dart RC, RADARS System Poison Center Group. Non-Dermal Routes Used in Fentanyl Patch Intentional Exposures. *Clin Toxicol.* 2015;53(7):702. **POSTER** 

#### PAINWeek

Bucher Bartelson B, Le Lait MC, Dart RC, Roland CL, Masters ET, Mardekian J, Green JL. Medical outcomes associated with unintended routes of prescription opioid abuse. PAINWeek 2015. Las Vegas, NV. September 2015. POSTER

Dart RC, Dargan PI, Wood DM, Besharat AC, Goodman EM, Iwanicki JL, Green JL. Chronic pain and non-medical use of opioids, benzodiazepines, and pregabalin in the United Kingdom. PAINWeek 2015. Las Vegas, NV. September 2015. POSTER

Iwanicki JL, Severtson SG, Green JL, Besharat AC, Dart RC. Abuse deterrent reformulation of controlled release oxycodone is associated with persistently declining rates of abuse and diversion by both oral and non-oral routes. PAINWeek 2015. Las Vegas, NV. September 2015. **POSTER** 

#### Society for Academic Emergency Medicine

Hatten BW, West NA, Severtson SG, Green JL, Dart RC. Prescription Opioid Exposures and Outcomes among Older Adults. Society for Academic Emergency Medicine National Conference. San Diego, CA. May 2015. ORAL PRESENTATION



Lebin JA, Murphy DL, Severtson SG, Dart RC. Reduced Street Price and Quantity Discounts for Diverted Extended Release OxyContin and Opana Following Crush Resistant Reformulation. Society for Academic Emergency Medicine National Conference. San Diego, CA. May 2015. **ORAL PRESENTATION** 

Murphy DL, Lebin JA, Severtson SG, Dart RC. Comparative Rates of Mortality and Severe Medical Effect Among Commonly Prescribed Opioid Analgesics: Calls to US Poison Centers Reporting Opioid Overdose Due to Intentional Abuse and Misuse Exposures. Society for Academic Emergency Medicine National Conference. San Diego, CA. May 2015. **ORAL PRESENTATION** 

#### 2014

### American College of Medical Toxicology

Green JL, Martinez EM, Severtson SG, Cicero TJ, Kurtz SP, Rosenblum A, Surratt HL, Dart RC, Lavonas EJ. Buprenorphine/naloxone abuse and diversion: film rates are less than tablet rates. American College of Medical Toxicology Annual Meeting. Phoenix, AZ. March 2014. **POSTER** 

Green JL, Martinez EH, Severtson SG, Dart RC, Lavonas EJ. Buprenorphine/naloxone pediatric ingestion: exposure rates differ between film and tablet formulations. American College of Medical Toxicology Annual Meeting. Phoenix, AZ. March 2014. **POSTER** 

#### American Pain Society

Le Lait C, Severtson G, Surratt H, Burke J, Bebarta V, Dart R. The role of tapentadol ER in the illicit market for opioid analgesics in the United States. 33<sup>rd</sup> Annual Scientific Meeting of the American Pain Society. Tampa, Florida. May 2014. **POSTER** 

Severtson G, Le Lait C, Green J, Dart R. Reformulation of extended release oxymorphone: changes in intentional abuse exposures before and after introduction of tamper resistant formulation. 33<sup>rd</sup> Annual Scientific Meeting of the American Pain Society. Tampa, Florida. May 2014. **POSTER** 

#### American Society of Addiction Medicine

Green JL, Martinez EM, Severtson SG, Dart RC, Lavonas EJ. Buprenorphine/naloxone pediatric ingestion: exposure rates differ between film and tablet formulations. 45<sup>th</sup> Annual Medical-Scientific Conference of the American Society of Addiction Medicine. Orlando, FL. April 2014. **POSTER** 

Green JL, Martinez EM, Severtson SG, Cicero TJ, Kurtz SP, Rosenblum A, Surratt HL, Dart RC, Lavonas EJ. Buprenorphine/naloxone abuse and diversion: film rates are less than tablet rates. 45<sup>th</sup> Annual Medical-Scientific Conference of the American Society of Addiction Medicine. Orlando, FL. April 2014. **POSTER** 

Wiegand TJ, Le Lait CMC, Green JL, Dart RC. Analysis of abuse of buprenorphine transdermal delivery system (Butrans<sup>®</sup>) using data from the RADARS<sup>®</sup> System Poison Center Program. 45<sup>th</sup> Annual Medical-Scientific Conference of the American Society of Addiction Medicine. Orlando, FL. April 2014. **POSTER** 


# **BIO International Convention**

Dart RC. Will Government and Payor Policies Encourage Innovation and Create Incentives for the Continued Development of Abuse Deterrent Formulations and Improvements to Existing Technologies. BIO International Convention. San Diego, CA. June 2014. INVITED PRESENTATION

#### **Canadian Pain Society**

Dart RC. "The Changing Landscape of Prescription Opioid Abuse and Misuse: A North American Epidemic." Canadian Pain Society 35<sup>th</sup> Annual Scientific Meeting. Quebec City, Quebec, Canada. May 2014. **INVITED PRESENTATION** 

# College on Problems of Drug Dependence



Green JL, Martinez EM, Severtson SG, Cicero TJ, Kurtz SP, Rosenblum A, Surratt HL, Dart RC, Lavonas EJ. Buprenorphine/Naloxone abuse and diversion: film rates are less than tablet rates. College on Problems of Drug Dependence Annual Meeting, San Juan, Puerto Rico. June 2014. **POSTER** 

Green JL, Martinez EM, Severtson SG, Dart RC, Lavonas EJ. Buprenorphine/Naloxone pediatric ingestion: exposure rates differ between film and tablet formulations. College on Problems of Drug Dependence Annual Meeting, San Juan, Puerto Rico. June 2014. **POSTER** 

Green JL, Martinez EM, Walcher S, Somaini L, Deruvo G, Desel H, Milanesi G, Sesana F, Guareschi M, McBride KE, Maremmani I, Rosenblum A, Parrino M, Cicero T, Dart RC. Global impact of prescription opioid misuse: Europe and US. College on Problems of Drug Dependence Annual Meeting, San Juan, Puerto Rico. June 2014. **POSTER** 

Le Lait MC, Severtson SG, Dasgupta N, Green JL, Hall A, Dart RC. The street prices of immediate release and extended release tapentadol are lower than other Schedule II opioid tablets/capsules. College on Problems of Drug Dependence Annual Meeting, San Juan, Puerto Rico. June 2014. **POSTER** 

Severtson SG, Le Lait MC, Green JL, Dart RC. Regional concentrations of Opana® ER abuse before and after introduction of a tamper resistant formulation in 2012. College on Problems of Drug Dependence Annual Meeting, San Juan, Puerto Rico. June 2014. **POSTER** 

Conference Board of Canada Symposium on Innovations and Policy Solutions for Addressing Rx Drug Abuse Dart RC. International Best Practices on Prescription Drug Abuse Surveillance. Conference Board of Canada Symposium on Innovations and Policy Solutions for Addressing Rx Drug Abuse. Ottawa, Canada. April 2014. INVITED PRESENTATION

#### EUROPAD

Fonseca, F, Green, JL, Maremmani, I, Touzeau, D, Walcher, S, Deruvo, G, Somaini, L, Martinez, D, Rossi, P, Torrens, M (2014). New Trends of Prescription Drug Use in Spain. *Heroin Addict Relat Clin Probl*, 46-47. **POSTER** 

Martinez EM, McBride KE, Guareschi M, Touzeau D, Walcher S, Deruvo G, Somaini L, Fonseca F, Bucher Bartelson B, Green JL, Dart RC, Maremmani I. European patients entering opioid addiction treatment whose primary drug is heroin differ from those whose primary drug is another opioid. 11<sup>th</sup> European Congress on Heroin Addiction & Related Clinical Problems. Glasgow, Scotland, UK. May 2014. **POSTER** 

Martinez EM, McBride KE, Guareschi M, Touzeau D, Walcher S, Deruvo G, Somaini L, Fonseca F, Bucher Bartelson B, Green JL, Dart RC, Maremmani I.Gender differences in patients entering treatment programs in Europe. 11<sup>th</sup> European Congress on Heroin Addiction & Related Clinical Problems. Glasgow, Scotland, UK. May 2014. **POSTER** 

Martinez EM, McBride KE, Guareschi M, Touzeau D, Walcher S, Deruvo G, Somaini L, Fonseca F, Bucher Bartelson B, Green JL, Dart RC, Maremmani I. European opiate addiction treatment programs: poly-opioid users are different than other patients seeking treatment. 11<sup>th</sup> European Congress on Heroin Addiction & Related Clinical Problems. Glasgow, Scotland, UK. May 2014. **POSTER** 

McBride KE, Martinez EM, Guareschi M, Touzeau D, Walcher S, Deruvo G, Somaini L, Fonseca F, Green JL, Dart RC, Maremmani I. Use of treatment history to identify drug use differences in european patients. 11<sup>th</sup> European Congress on Heroin Addiction & Related Clinical Problems. Glasgow, Scotland, UK. May 2014. **POSTER** 

#### European Association of Poisons Centres and Clinical Toxicologists

Dart RC. "International Overview of Prescription Drug Misuse." XXXIV Annual International Congress of the European Association of Poisons Centres and Clinical Toxicologists. Brussels, Belgium, May 2014. KEYNOTE LECTURE



Dart RC. "What's New in Drug Abuse." XXXIV Annual International Congress of the European Association of Poisons Centres and Clinical Toxicologists. Brussels, Belgium, May 2014. SYMPOSIUM PRESENTATION

Green JL, Martinez EM, Bucher Bartelson B, Desel H, Milanesi G, Sesana F, de Vries I, Kupferschmidt H, Thomas SHL, Thompson JP, McBride KE, Dart RC. Global Toxicosurveillance Network (GTNet): Characterizing prescription opioid exposures reported to european poison centres. XXXIV Annual International Congress of the European Association of Poisons Centres and Clinical Toxicologists. Brussels, Belgium. May 2014. **POSTER** 

Green JL, Martinez EM, Walcher S, Somaini L, Deruvo G, Desel H, Milanesi G, Sesana F, Guareschi M, McBride KE, Maremmani I, Dart RC. Prescription opioid misuse in Europe: from opioid treatment programs to poison centres. XXXIV Annual International Congress of the European Association of Poisons Centres and Clinical Toxicologists. Brussels, Belgium, May 2014. POSTER

### **EUROTOX**

Dart RC. Misuse of Prescription Psychotropic Drugs, Emerging Data from Europe. 50<sup>th</sup> Congress of the European Societies of Toxicology. Edinburgh, Scotland. September 2014. **INVITED PRESENTATION** 

#### Human Abuse Liability & Abuse Deterrent Formulations Conference

Dart RC. New Data, Directions and Product Strategies for ADFs to Prevent Initial Addiction. Human Abuse Liability & Abuse Deterrent Formulations Conference. Silver Spring, MD. November 2014. INVITED PRESENTATION

#### International Conference on Opioids

Severtson SG, Bucher Bartelson B, Green JL, Dart RC. Diversion of Opana ER declined following introduction of a tamper resistant formulation. International Conference on Opioids. Boston, MA. June 2014. **POSTER** 

#### International Society of Addiction Medicine

Dart RC. USA issues on prescription opioids. 16th International Society of Addiction Medicine Annual Meeting, Yokohama, Japan. October 2014. SYMPOSIUM PRESENTATION

Dart RC, Surratt HL, Cicero TJ, Parrino MW, Severtson SG, Green JL. Bending the curve of opioid analgesic abuse in the United States. 16th International Society of Addiction Medicine Annual Meeting, Yokohama, Japan. October 2014. SYMPOSIUM PRESENTATION

# National Rx Drug Abuse Summit


Dart RC. "Pharmacy: Impact of Abuse-Deterrent Formulations." 2014 National Rx Drug Abuse Summit. Atlanta, GA. April 2014. INVITED PRESENTATION

# North American Congress of Clinical Toxicology

Bebarta VS, Severtson SG, Green JL, Dart RC. An analysis of the abuse and associated deaths of immediate release opioid analgesics as compared to extended release formulations in the United States. North American Congress of Clinical Toxicology Annual Meeting. New Orleans, LA. October 2014. **POSTER** 

Brown KR, Le Lait MC, Dart RC. Pediatric serious adverse events after exposure to immediate and extended release opioids. North American Congress of Clinical Toxicology Annual Meeting. New Orleans, LA. October 2014. **POSTER** 

Fischer LJ, Severtson SG, Dart RC. Age differences in intentional abuse cases mentioning hydrocodone products versus schedule II opioids. North American Congress of Clinical Toxicology Annual Meeting. New Orleans, LA. October 2014. **POSTER** 



Lavery SA, Le Lait MC, Severtson SG, West NA, Dart RC. Factors associated with non-medical use of stimulants among college students. North American Congress of Clinical Toxicology Annual Meeting. New Orleans, LA. October 2014. **POSTER** 

West NA, Severtson SG, Green JL, and Dart RC. Trends among older adults in intentional prescription opioid exposure calls to poison centers. North American Congress of Clinical Toxicology Annual Meeting. New Orleans, LA. October 2014. **POSTER** 

PAINWeek

West NA, Le Lait MC, Surratt H, Burke JJ, Kurtz SP, Dasgupta N, Bebarta VS, Dart RC. Diversion and illicit sale of extended release tapentadol in the United States. PAINWeek 2014. Las Vegas, NV. September 2014. POSTER

US Food and Drug Administration Office of Surveillance and Epidemiology Safety Seminary Dart RC. Post Marketing Surveillance of Prescription Drugs – Current Data and Issues. US Food and Drug Administration Office of Surveillance and Epidemiology Safety Seminar. Silver Spring, MD. August 2014. INVITED PRESENTATION

# World Health Organization Expert Committee on Drug Dependence Opening Meeting

Dart RC. Tapentadol – Abuse and Diversion in the US (RADARS® System). World Health Organization (WHO) Expert Committee on Drug Dependence (EDCC). Geneva, Switzerland. June 2014. INVITED PRESENTATION

#### 2013

# American Association for the Treatment of Opioid Dependence

Green JL. "New Substances of Abuse in Europe: Results from a EUROPAD Pilot Study in Four Countries." American Association for the Treatment of Opioid Dependence Conference. Philadelphia, PA. November 2013. INVITED PRESENTATION

# American Pain Society

Dart R, Severtson S, Patrick J, Webster J. Abuse, misuse, and diversion of hydromorphone since the introduction of the extended-release formulation (EXALGO®). American Pain Society Annual Meeting. New Orleans, LA. May 2013. **POSTER** 

Lavonas E, Bucher Bartelson B, Severtson S, Davis J, Baker G, Vorsanger G, Dart R. Abuse and diversion of immediaterelease prescription opioids: 30 months of data from the RADARS® System. American Pain Society Annual Meeting. New Orleans, LA. May 2013. **POSTER** 

Severtson S, Davis J, Le Lait M, Bucher-Bartelson B, Dart R. Use of both individuals filling prescriptions and population rates in assessing abuse potential of prescription opioids. American Pain Society Annual Meeting. New Orleans, LA. May 2013. **POSTER** 

Surratt H, Kurtz S, Cicero T, Dart R, Baker G, Vorsanger G. Street prices of prescription opioids diverted to the illicit market: data from a national surveillance program. American Pain Society Annual Meeting. New Orleans, LA. May 2013. **POSTER** 

# American Society of Addiction Medicine

Lavonas EJ, Severtson SG, Bucher-Bartelson B, Green JL, Cicero T, Kurtz SP, Rosenblum A, Surratt HL, Dart RC. Buprenorphine/Naloxone film diversion and abuse rates are less than tablet formulations. American Society of Addition Medicine Annual Medical-Scientific Conference. Chicago, IL. April 2013. **POSTER** 

# Asia Pacific Association of Medical Toxicology



Green JL. "Strategies to Reduce Prescription Opioid Misuse in the USA." Asia Pacific Association of Medical Toxicology International Scientific Congress. Dubai, United Arab Emirates. November 2013. INVITED PRESENTATION

#### **Centers for Disease Control and Prevention PROTECT**

Green JL. Key Findings from "Root Causes, Clinical Effects, and Outcomes Of Unintentional Exposures to Buprenorphine by Young Children". Centers for Disease Control and Prevention (CDC) PROTECT Meeting. Atlanta, GA. September 2013. INVITED PRESENTATION

### College on Problems of Drug Dependence

Dart RC. "Changing Patterns of Abuse Reported to Poison Centers Following Introduction of Reformulated Extended Release Oxycodone." College on Problems of Drug Dependence Annual Meeting. San Diego, CA. June 2013. INVITED PRESENTATION

Fonseca F, Green JL, Maremmani I, Touzeau D, Walcher S, Deruvo G, Somaini L, Martínez D, Roig J, Torrens M. Studying new trends of prescription drug use in Europe: The European Opioid Treatment Patient Survey. National Institute on Drug Abuse (NIDA) International Forum at the College on Problems of Drug Dependence (CPDD) Annual Meeting. San Diego, CA. June 2013. **POSTER** 

Lowitz KA, Le Lait MC, Severtson SG, Dart RC. Evaluation of trends in abuse of stimulants in high school and college age persons using RADARS® System Data. College on Problems of Drug Dependence Annual Meeting. San Diego, CA. June 2013. **POSTER** 

Rosenblum A, Fong C, Cleland C. Non-opioid substance use among opioid-dependent patients enrolling in opioid treatment programs: A latent class analysis. College on Problems of Drug Dependence Annual Meeting. San Diego, CA. June 2013. **POSTER** 

Severtson SG, Le Lait MC, Bucher Bartelson B, Dart RC Age trends in abuse calls to poison centers involving prescription opioids. College on Problems of Drug Dependence Annual Meeting. San Diego, CA. June 2013. **POSTER** 

#### Colorado Methamphetamine Task Force

Green JL. RADARS® System. Colorado Methamphetamine Task Force. Denver, CO. February 2013. INVITED PRESENTATION

#### Colorado School of Public Health

Martinez E. "Trends in Prescription Opioid Exposures in Colorado from 2003-2012 Using Data from the RADARS® System Poison Center Program." Colorado School of Public Health: Epidemiology Discussion Group. Denver, CO. May 2013. INVITED PRESENTATION

#### European Association of Poisons Centres and Clinical Toxicologists

Dart RC. "Prescription Drugs Purchased Through the Internet: Who are the Users?" International Congress of the European Association of Poisons Centres and Clinical Toxicologists. Copenhagen, Denmark. May 2013. KEYNOTE LECTURE

Green JL, Desel H, Milanesi G, Sesana F, Brown JA, Gunja N, Kupferschmidt H, De Vries I, Campbell A, Thomas SHL, Thompson JP, Severtson G, Poppish L, Gmerek B, Dart R. Unintentional pediatric opioid exposures as reported to the Global Toxicosurveillance Network (GTNet) from 2008-2010. International Congress of the European Association of Poisons Centres and Clinical Toxicologists. Copenhagen, Denmark. May 2013. **POSTER** 

#### European Conference and International Symposium



Dart R. Are Abuse Deterrent Formulations Effective? Colloque Européen et International Toxicomanies Hépatites SIDA European Conference and International Symposium (THS-11: Addiction-Hepatitis-AIDS). Biarritz, France. October 2013. INVITED PRESENTATION

Dart R. Prescription Opioid Analgesic Dependence and Addiction: Experience in the United States. Colloque Européen et International Toxicomanies Hépatites SIDA European Conference and International Symposium (THS-11: Addiction-Hepatitis-AIDS). Biarritz, France. October 2013. INVITED PRESENTATION

# GLAAD

Dart RC. "Diversion, Misuse and Trafficking of Methadone and Buprenorphine." Global Addiction & EUROPAD Joint Conference. Pisa, Italy. May 2013. INVITED PRESENTATION

### International Conference on Opioids

Lavonas EJ, Bucher-Bartelson B, Severtson SG, Davis JM, Baker G, Vorsanger GJ, Dart RC. Abuse and diversion of immediate-release prescription opioids: 30 months of data from the RADARS® System. International Conference on Opioids Annual Conference. Boston, MA. June 2013. **POSTER** 

Lavonas E, Severtson S, Le Lait M, Lowitz K, Green J, Poppish L, Dart RC. Changes in oxymorphone abuse rates following introduction of a crush-resistant formulation. International Conference on Opioids Annual Conference. Boston, MA. June 2013. **POSTER** 

Surratt H, Kurtz S, Cicero T, Dart R, Baker G, Vorsanger G. Street prices of prescription opioids diverted to the illicit market: data from a national surveillance program. International Conference on Opioids Annual Conference. Boston, MA. June 2013. **POSTER** 

#### International Society of Addiction Medicine

Lavery SA, Martinez EM, Bucher Bartelson B, McBride KE, Deruvo G, Somaini L, Fonseca F, Guareschi M, Green JL, Dart RC, Maremmani I. Primary drug of health care workers in Italy and Spain using Europad pilot study data. International Society of Addiction Medicine Annual Meeting. Kuala Lumpur, Malaysia. November 2013. **POSTER** 

Martinez EM, McBride KE, Bucher Bartelson B, Fonseca F, Deruvo G, Somaini L, Walcher S, Touzeau D, Guareschi M, Green JL, Dart RC, Maremmani I. European and U.S. patient self-reported primary drug and percent of endorsers injecting at treatment intake. International Society of Addiction Medicine Annual Meeting. Kuala Lumpur, Malaysia. November 2013. **POSTER** 

#### National Governors Association Policy Academy

Lavonas EJ. "Prescription Drug Abuse: Colorado and National Data." Colorado In-State Policy Workshop, National Governors Association Policy Academy: Reducing Prescription Drug Abuse. Denver, CO. April 2013. INVITED PRESENTATAION

#### North American Congress of Clinical Toxicology

Brown KR, Severtson SG, Dart RC, RADARS® System Poison Center Group. Intentional exposures to opioids reported by health care workers. North American Congress of Clinical Toxicology Annual Meeting. Atlanta, GA. September 2013. **POSTER** 

Fischer LJ, Poppish L, Le Lait MC, Bucher Bartelson B, Dart RC, RADARS® System Poison Center Group. Geographic description of opioid exposures in pregnant women within the US. North American Congress of Clinical Toxicology Annual Meeting. Atlanta, GA. September 2013. **POSTER** 

Green JL, Bucher Bartelson B, Desel H, Ochsenfahrt G, Sesana F, Milanesi G, Kupferschmidt H, Gunja N, Brown JA, McBride KE, Dart RC. Trends in intentional and unintentional prescription opioid exposures reported to Poison Centers



(PC) in Australia, Germany, Italy, Switzerland and the United States, 2007-2012. North American Congress of Clinical Toxicology Annual Meeting. Atlanta, GA. September 2013. **POSTER** 

Lavery SA, Le Lait MC, Bucher Bartelson B, Poppish L, Green JL, Dart RC, RADARS® System Poison Center Group. Intentional exposures to prescription opioids in rural areas of the United States. North American Congress of Clinical Toxicology Annual Meeting. Atlanta, GA. September 2013. **POSTER** 

Lavonas EJ. "Young Child Exposures to Prescription Medication: Do Formulation and Packaging Matter?" North American Congress of Clinical Toxicology Annual Meeting. Atlanta, GA. September 2013. INVITED PRESENTATION

Winter EJ, Martinez EM, Lavonas EJ, Bucher Bartelson B, Poppish L, Green JL, Dart RC, RADARS® System Poison Center Group. Micromedex® clarification of Suboxone® products increases coding accuracy in the RADARS® System Poison Center Program. North American Congress of Clinical Toxicology Annual Meeting. Atlanta, GA. September 2013. **POSTER** 

### Nurse-Physician Advisory Taskforce for Colorado Healthcare

Dart RC. "Prescription Opioid Dependence and Addiction: Experience in the United States." Nurse-Physician Advisory Taskforce for Colorado Healthcare Quad-Regulator Meeting. Denver, CO. September 2013. INVITED PRESENTATION

#### US Food and Drug Administration Advisory Committee

Green JL. "Buprenorphine RADARS® System Analysis." FDA Psychopharmacologic Drugs Advisory Committee Meeting. Silver Spring, MD. March 2013. INVITED PRESENTATION

Lavonas E. "Prescription Drug Monitoring Programs: Evidence for Effectiveness." FDA Drug Safety and Risk Management Advisory Committee Meeting. Silver Spring, MD. January 2013. INVITED PRESENTATION

#### **US Food and Drug Administration Public Hearing**

Green JL. "Impact of Approved Drug Labeling on Chronic Opioid Therapy: RADARS® System Findings." FDA Impact of Approved Drug Labeling on Chronic Opioid Therapy Part 15 Public Hearing. Bethesda, MD. February 2013. INVITED PRESENTATION

2012

# Abuse Liability Evaluation for Research, Treatment, and Training Working Group

Dart RC. Classifying abuse-related events: the RADARS® System experience. Abuse Liability Evaluation for Research, Treatment, and Training Working Group. Washington DC. November 2012. INVITED PRESENTATION

#### American Academy of Addiction Psychiatry

Lavonas EJ, Severtson G, Murrelle EL, Ruby J, Bucher Bartelson B, Dart RC. Unintentional exposures to buprenorphine/naloxone tablets and oral film among children less than 6 years old. American Academy of Addiction Psychiatry Annual Meeting. Aventura, FL. December 2012. **POSTER** 

#### American Academy of Pain Management

Chilcoat H, Severtson SG, Bucher Bartelson B, Davis JD, Muñoz A, Schneider MF, Coplan P, Dart RC. Extended Release Oxycodone Abuse After Reformulation. American Academy of Pain Management Annual Meeting. Phoenix, AZ. September 2012. **POSTER** 

Chilcoat H, Davis JD, Severtson SG, Bucher Bartelson B, Muñoz A, Schneider MF, Coplan P, Dart RC. Extended Release Oxycodone Diversion After Reformulation. American Academy of Pain Management Annual Meeting. Phoenix, AZ. September 2012. **POSTER** 



## American Academy of Pain Medicine

Dart RC, Adams E, Bucher-Bartelson B, Baker G, Pitner J, Vorsanger G. Tapentadol abuse: the first 18 months. American Academy of Pain Medicine Annual Meeting. Palm Springs, CA. February 2012. **POSTER** 

Dart RC, Adams E, Bucher-Bartelson B, Baker G, Pitner J, Vorsanger G. Trends in the non-medical use of tapentadol immediate release by college students. American Academy of Pain Medicine Annual Meeting. Palm Springs, CA. February 2012. **POSTER** 

### American Academy of Physical Medicine and Rehabilitation

Chilcoat H, Bucher Bartelson B, Coplan P, Dart RC, Davis J, Green JL, Muñoz A, Schneider MF, Severtson SG. Difference in rates of abuse following reformulation of extended release (ER) oxycodone using data from the RADARS® System Poison Center program. American Academy of Physical Medicine and Rehabilitation Annual Meeting. Atlanta, GA. November 2012. **POSTER** 

Chilcoat H, Bucher Bartelson B, Coplan P, Dart RC, Davis J, Green JL, Muñoz A, Schneider MF, Severtson SG, Surratt H. Changes in diversion rates following the introduction of a reformulated extended release oxycodone product. American Academy of Physical Medicine and Rehabilitation Annual Meeting. Atlanta, GA. November 2012. **POSTER** 

### American Association for the Treatment of Opioid Dependence

Rosenblum A, Fong C. Heroin use is a risk factor for injecting prescription opioids. American Association for the Treatment of Opioid Dependence National Conference. Las Vegas, NV. April 2012. **POSTER** 

# American College of Emergency Physicians

Davis J, Severtson SG, Bartelson BB, Muñoz A, Schneider MF, Surratt H, Coplan P, Chilcoat H, Green JL, Dart RC. Changes in diversion rates following the introduction of a reformulated extended release oxycodone product. American College of Emergency Physicians Scientific Assembly. Denver, CO. October 2012. **POSTER** 

Severtson SG, Bartelson BB, Davis J, Muñoz A, Schneider MF, Coplan P, Chilcoat H, Green JL, Dart RC. Difference in rates of abuse following reformulation of extended release (ER) oxycodone using data from the RADARS® System Poison Center program. American College of Emergency Physicians Scientific Assembly. Denver, CO. October 2012. **POSTER** 

#### American Pain Society

Severtson SG, Bucher Bartelson B, Chilcoat H, Coplan P, Surratt H, Dart RC. A comparison of the street price of original and reformulated OxyContin® and immediate release (IR) oxycodone products. American Pain Society Annual Meeting. Honolulu, HI. May 2012. **POSTER** 

#### Association for Medical Education and Research in Substance Abuse

Lavonas EJ, Severtson G, Murrelle EL, Ruby J, Bucher Bartelson B, Dart RC. Unintentional exposures to buprenorphine/naloxone tablets and film among children less than 6 years old: initial experience from the RADARS® System Poison Center Program. Association for Medical Education and Research in Substance Abuse Annual Meeting. Bethesda, MD. November 2012. **POSTER** 

#### California Society of Addiction Medicine

Dart RC. RADARS® System Abuse/Tamper Deterrent Formulations. California Society of Addiction Medicine Opioid Pre-Conference Workshop. San Francisco, CA. September 2012. INVITED PRESENTATION

# College on Problems of Drug Dependence

Dart RC. Buprenorphine-naloxone as an abuse-deterrent drug. College on Problems of Drug Dependence Annual Meeting. Palm Springs, CA. June 2012. INVITED PRESENTATION



Dasgupta N, Menone CM, Dart R, Brownstein JS. Assessing abuse deterrence strategies for pharmaceuticals using crowdsourcing for black market street prices. College on Problems of Drug Dependence Annual Meeting. Palm Springs, CAL. June 2012. **POSTER** 

Severtson SG, Bartelson BB, Davis JM, Muñoz A, Schneider MF, Surratt H, Coplan P, Chilcoat H, Dart RC. Reduction in OxyContin® diversion cases following the introduction of reformulated OxyContin. College on Problems of Drug Dependence Annual Meeting. Palm Springs, CA. June 2012. **POSTER** 

Surratt H, Kurtz SP, Cicero TJ, Dart RC. Street prices of prescription opioids diverted to the illicit market. College on Problems of Drug Dependence Annual Meeting. Palm Springs, CA. June 2012. **POSTER** 

### **Drug Information Association**

Green JL. RADARS® System: mosaic approach to opioid surveillance and REMS evaluation. Drug Information Association Annual Meeting. Philadelphia, PA. June 2012. INVITED PRESENTATION

# European Association of Poisons Centres and Clinical Toxicologists

Green JL, Thomas SHL, Thompson JP, Kupferschmidt H, Desel H, Gunja N, Brown JA, Sesana F, Milanesi G, de Vries I, Dart RC. International Perspective of Prescription Opioid Exposures Reported to Poison Centres from 2007-2010. International Congress of the European Association of Poisons Centres and Clinical Toxicologists. London, England. May 2012. **POSTER** 

Green JL, Thomas SHL, Thompson JP, Kupferschmidt H, Desel H, Gunja N, Brown JA, Sesana F, Milanesi G, de Vries I, Dart RC. International Perspective on Prescription Stimulant Exposures Reported to Poison Centres from 2007-2010. International Congress of the European Association of Poisons Centres and Clinical Toxicologists. London, England. May 2012. **POSTER** 

# International Association for the Study of Pain

Bucher Bartelson B, Severtson SG, Davis JM, Surratt H, Chilcoat H, Coplan P, Green JL, Dart RC. A comparison of the street price of original and reformulated ER oxycodone product. International Association for the Study of Pain Annual Meeting. Milan, Italy. August 2012. **POSTER** 

Davis JM, Severtson SG, Bucher Bartelson B, Muñoz A, Schneider MF, Surratt H, Chilcoat H, Coplan P, Green JL, Dart RC. Reduction in Extended Release (ER) Oxycodone Diversion Rates Following the Introduction of a Reformulated ER Oxycodone Product. International Association for the Study of Pain Annual Meeting. Milan, Italy. August 2012. **POSTER** 

Severtson SG, Bucher Bartelson B, Davis JM, Muñoz A, Schneider MF, Coplan P, Chilcoat H, Green JL, Dart RC. Difference in rates of abuse following reformulation of extended release (ER) oxycodone using data from the Radars® System Poison Center Program. International Association for the Study of Pain Annual Meeting. Milan, Italy. August 2012. **POSTER** 

# International Conference on Pharmacoepidemiology & Therapeutic Risk Management

Davis JM, Severtson SG, Bucher Bartelson B, Muñoz A, Schneider MF, Surratt H, Chilcoat H, Coplan P, Green JL, Dart RC. Changes in diversion rates following the introduction of a reformulated extended release oxycodone product. *Pharmacoepidemiol Drug Saf.* 2012; 21(Suppl 3):450-451. **POSTER** 

Severtson SG, Bucher Bartelson B, Davis JM, Muñoz A, Schneider MF, Coplan P, Chilcoat H, Green JL, Dart RC. Differences in rates of abuse following reformulation of extended release (ER) oxycodone using data from the RADARS<sup>®</sup> Poison Center Program. *Pharmacoepidemiol Drug Saf.* 2012; 21(Suppl 3):221. **POSTER** 

# International Society of Addiction Medicine



Maremanni I, Green JL. Trends of Opioid Misuse and Diversion: Lessons for Europe from the USA. International Society of Addiction Medicine RBP Sponsored Symposium. Geneva, Switzerland. October 2012. INVITED PRESENTATION

#### International Society for Pharmacoeconomics and Outcomes Research

Lavonas EJ, Severtson SG, Murrelle EL, Ruby J, Bucher Bartelson B, Dart RC. Unintentional exposures to buprenorphine/naloxone tablets and oral film among children less than 6 years old. International Society for Pharmacoeconomics and Outcomes Research European Congress. Berlin, Germany. November 2012. POSTER

### National Association of State Controlled Substance Authorities

Green JL. The impact of tamper resistant formulations on prescription drug abuse. National Association of State Controlled Substance Authorities Conference. Scottsdale, AZ. October 2012. INVITED PRESENTATION

### North American Congress of Clinical Toxicology

Brown KR, Severtson SG, Dart RC, RADARS® System Poison Center Group. RADARS® System poison center intentional exposures to OxyContin®: a look at the differences in rates of abuse via unintended routes before and after reformulation intervention. North American Congress of Clinical Toxicology Annual Meeting. Las Vegas, NV. October 2012. POSTER

Bucher Bartelson B, Green JL, Desel H, Ochsenfahrt G, Sesana F, Milanesi G, Dart RC. Intentional and Unintentional Prescription Opioid Exposures in Italy, Germany and the United States. North American Congress of Clinical Toxicology Annual Meeting. Las Vegas, NV. October 2012. **ORAL PRESENTATION** 

Davis JM, Bucher-Bartelson B, Severtson SG, Dart RC, RADARS® System Poison Center Group. Regional differences in seasonal trends in suicide exposures to prescription opioids as reported to poison centers participating in the RADARS® System North American Congress of Clinical Toxicology Annual Meeting. Las Vegas, NV. October 2012. **POSTER** 

Fischer LJ, Davis JM, Bucher-Bartelson B, Poppish L, Dart RC, RADARS® System Poison Center Group. Prescription opioid and stimulant use among pregnant women: surveillance by poison control centers participating in the RADARS® System. North American Congress of Clinical Toxicology Annual Meeting. Las Vegas, NV. October 2012. POSTER

Green JL, Bucher-Bartelson B, Desel H, Ochsenfahrt G, Sesana F, Milanesi G, Dart RC Intentional and Unintentional Prescription Stimulant Exposures in Italy, Germany and the United States. North American Congress of Clinical Toxicology Annual Meeting. Las Vegas, NV. October 2012. **POSTER** 

Winter EJ, Davis JM, Bucher-Bartelson B, Westberry R, Green JL, Lavonas EJ, Dart RC, RADARS® System Poison Center Group. Systematic misclassification in product-specific coding of poison center data: the example of buprenorphine in the RADARS® System poison center program. North American Congress of Clinical Toxicology Annual Meeting. Las Vegas, NV. October 2012. **POSTER** 


### **Ontario Methadone Prescribers Conference**

Lavonas E. Abuse, Misuse, and Diversion of Prescription Opioids: Evaluating the Problem and Proposed Solutions. Ontario Methadone Prescribers Conference. Toronto, Canada. November 2012. INVITED PRESENTATION

#### Pain Care Forum

Green JL. RADARS® System Abuse Deterrent Formulations (ADFs) Analyses. Pain Care Forum. Washington, DC. February 2012. INVITED PRESENTATION

Lavonas E. Measuring Interventions to Reduce Prescription Drug Misuse, Abuse, and Diversion. Pain Care Forum. Washington, DC. June 2012. INVITED PRESENTATION



Lavonas E. Pain Care Forum – RADARS System Update. Pain Care Forum. Washington, DC. June 2012. INVITED PRESENTATION

#### PAINWeek

Dart RC, Adams E, Bucher-Bartelson B, Baker G, Pitner J, Vorsanger G. Tapentadol abuse: the first 18 months. PAINWeek 2012. Las Vegas, NV. September 2012. **POSTER** 

Dart RC, Adams E, Bucher-Bartelson B, Baker G, Pitner J, Vorsanger G. Trends in the non-medical use of Nycynta® by college students. PAINWeek 2012. Las Vegas, NV. September 2012. **POSTER** 

Surratt H, Kurtz S, Cicero T, Dart R. Street prices of prescription opioids diverted to the illicit market. PAINWeek 2012. Las Vegas, NV. September 2012. **POSTER** 

#### 2011

#### American Academy of Pain Medicine

Kurtz SP, Surratt HL, Cicero TJ, Ibanez GE, Rosenblum A, Dart RC, Internet-based diversion of prescription opioids. American Academy of Pain Medicine Annual Meeting. National Harbor, MD. March 2011. **POSTER** 

#### American Public Health Association

Davis J, Miller H, Winter E, Dart RC. Suicidal behaviors with prescription drugs in individuals over 50 years of age as identified by the RADARS® System Poison Center Program. American Public Health Association Annual Meeting. Washington, DC. October 2011. **POSTER** 

Davis J, Miller H, Winter E, Dart RC. Suicidal behaviors with prescription drugs in individuals under 50 years of age as identified by the RADARS® System Poison Center Program. American Public Health Association Annual Meeting. Washington, DC. October 2011. **POSTER** 

Wheat A, Davis J, Bartelson BB, Buchholtz C, Dart RC. Is drug source a predictor of severity of non-medical prescription drug use among college students? Do source predictors vary by Gender? American Public Health Association Annual Meeting. Washington, DC. October 2011. **POSTER** 

#### College on Problems of Drug Dependence

Davis J, Buchholtz C, Wheat A, Bucher Bartelson B, Dart RC. Predictors of moderate, substantial or severe problems associated with drug abuse in college students reporting recent non-medical opioid use. College on Problems of Drug Dependence Annual Meeting. Hollywood, FL. June 2011. **POSTER** 


Rosenblum A, Fong C, Parrino M. Heroin use is a risk factor for injecting prescription opioids. College on Problems of Drug Dependence Annual Meeting. Hollywood, FL. June 2011. **POSTER** 

Wheat A, Buchholtz C, Davis J, Dart RC. Predictors of severe prescription drug abuse among college students using the RADARS System College Survey. College on Problems of Drug Dependence Annual Meeting. Hollywood, FL. June 2011. **POSTER** 

#### European Association of Poisons Centres and Clinical Toxicologists

Green JL, Dart RC, Bucher Bartelson B. Buprenorphine abuse in the United States: Comparison to methadone using five surveillance programs simultaneously. International Congress of the European Association of Poisons Centres and Clinical Toxicologists. Dubrovnik, Croatia. May 2011. **POSTER** 

#### International Conference on Pharmacoepidemiology & Therapeutic Risk Management



Wheat A, Davis J, Bucher Bartelson B, Dart RC. The interaction between gender and severity of prescription drug abuse among college students on ability to correctly identify photos of recently abused drugs. International Conference on Pharmacoepidemiology & Therapeutic Risk Management Annual Meeting. Chicago, IL. August 2011. **POSTER & PRESENTATION** 

# North American Congress of Clinical Toxicology

Winter EJ, Buchholtz C, Davis JM, Severtson SG, Dart RC, RADARS® System Poison Center Group. Poison center calls for intentional exposures to opioids are highly correlated with retail availability in the RADARS System Poison Center Program. North American Congress of Clinical Toxicology Annual Meeting. Washington, DC. September 2011. POSTER

#### 2010

#### American Academy of Addiction Psychiatry

Varughese S, Rosen S, Ertischek MD, Sembower MA, St. Jean E, Schnoll S. Non-medical use surveillance and signal identification of lisdexamfetamine dimesylate, a pro-drug stimulant to treat ADHD. American Academy of Addiction Psychiatry Annual Meeting. Boca Raton, FL. December 2010. **POSTER** 

#### American Academy of Child and Adolescent Psychiatry

Varughese S, Rosen S, Lindholm A, Ertischek MD, Sembower MA, Schnoll S. Non-medical use surveillance and signal identification of lisdexamfetamine dimesylate, a pro-drug stimulant for the treatment of ADHD. American Academy of Child and Adolescent Psychiatry Annual Meeting. New York, NY. October 2010. **POSTER** 

#### American Psychiatric Association

Varughese S, Rosen S, Ertischek MD, Sembower MA, St. Jean E, Schnoll S. Non-medical use surveillance and signal identification of Lisdexamfetamine Dimesylate, a pro-drug stimulant for the treatment of ADHD. American Psychiatric Association Annual Meeting. New Orleans, LA. May 2010. **POSTER** 

### American Public Health Association

Reifler LM, Droz D, Bucher Bartelson B, Bailey JE, Schnoll S, Dart RC. RADARS<sup>®</sup> System Poison Center opioid abuse and misuse rates over time in states with and without active prescription monitoring programs. American Public Health Association Annual Meeting. Denver, CO. November 2010. **POSTER** 

#### **Canadian Psychiatric Association**

Varughese S, Rosen S, Lindholm A, Ertischek MD, Sembower MA, St. Jean E, Schnoll S. Non-medical use surveillance and signal identification of lisdexamfetamine dimesylate, a pro-drug stimulant for the treatment of Attention-Deficit Hyperactivity Disorder. Canadian Psychiatric Association Annual Meeting. Toronto, Canada. September 2010. **POSTER** 

#### Center for Substance Abuse Treatment

Dart RC, Baily E. Methadone morbidity and mortality: current data and trends from the RADARS® System. Center for Substance Abuse Treatment. Methadone Mortality - Reassessment 2010. Washington, DC. July 2010. INVITED **PRESENTATION** 

Dasgupta N. Buprenorphine Data from The RADARS® System. Center for Substance Abuse Treatment. Buprenorphine Mortality - Reassessment 2010. Washington, DC. May 2010. INVITED PRESENTATION

#### College on Problems of Drug Dependence

Buchholtz C, Reifler LM, Bailey JE, Dart RC. Chewing then swallowing in self-reported non-medical opioid use by college students as reported by the Researched Abuse, Diversion and Addiction-Related Surveillance System. College on Problems of Drug Dependence Annual Meeting. Scottsdale, AZ. June 2010. **POSTER** 



Cleland C, Rosenblum A, Fong C, Parrino M, Magura S. Prescription opioid abuse predicts first admission into methadone maintenance treatment. College on Problems of Drug Dependence Annual Meeting. Scottsdale, AZ. June 2010. **POSTER** 

Schnoll SH, Sembower MA, Shiffman S, Varughese S, Ertischek MD, St. Jean E, Rosen S. Non-medical use of extended release prescription stimulants: An examination of amphetamine and methylphenidate. College on Problems of Drug Dependence Annual Meeting. Scottsdale, AZ. June 2010. **POSTER** 

Zosel A, Bailey JE, Buchholtz C, Ross E, Dart RC. Methadone-associated deaths by formulation as reported by the Researched Abuse, Diversion and Addiction-Related Surveillance System. College on Problems of Drug Dependence Annual Meeting. Scottsdale, AZ. June 2010. **POSTER** 

### North American Congress of Clinical Toxicology

Buchholtz C, Thomasset C, Bailey JE, Dart RC. Administration routes involved in non-medical use of long-acting opioids in the RADARS<sup>®</sup> System College Survey and Poison Center Programs. North American Congress of Clinical Toxicology Annual Meeting. Denver, CO. October 2010. **POSTER** 

Reifler LM, Droz D, Bartelson BB, Bailey JE, Schnoll S, Dart RC, RADARS System Poison Center Group. Reduction over time in RADARS<sup>®</sup> System Poison Center opioid abuse/misuse rates associated with prescription monitoring programs. North American Congress of Clinical Toxicology Annual Meeting. Denver, CO. October 2010. **POSTER** 

Zosel A, Bodmer M, Buchholtz C, Bailey JE, Dart RC, RADARS® System Poison Center Group. Characterization of prescription stimulant exposures using RADARS® System poison center program data. North American Congress of Clinical Toxicology Annual Meeting. Denver, CO. October 2010. **POSTER** 

# Pacific Drug Safety Summit

Bogdan, G. A Framework for Opioid REMS Assessment. Annual Pacific Drug Safety Summit. San Francisco, CA. September 2010. INVITED PRESENTATION

#### 2009

#### College on Problems of Drug Dependence

Bailey JE, Spiller HA, Spiller SS, Dart RC. Does day of week impact prevalence of prescription drug abuse? College on Problems of Drug Dependence Annual Meeting. Reno, NV. June 2009. **POSTER** 


Cleland C, Rosenblum A, Fong C, Parrino M, Magura S. Age effects on heroin and prescription opioid abuse among enrollees into methadone maintenance treatment. College on Problems of Drug Dependence Annual Meeting. Reno, NV. June 2009. **POSTER** 

Montoya AM, Zolot LM, Bailey JE, Dart RC. Motives for non-medical prescription opioid use among RADARS<sup>®</sup> System College Survey respondents–Indication of a substance abuse disorder? College on Problems of Drug Dependence Annual Meeting. Reno, NV. June 2009. (*presented by JE Bailey*). **ORAL PRESENTATION** 

Spiller HA, Spiller SS, Bailey JE, Dart RC. Does prescription drug abuse take a holiday? College on Problems of Drug Dependence Annual Meeting. Reno, NV. June 2009. **POSTER** 

Zosel AE, Kirtland M, Bailey JE, Dart RC. Characterization of adolescent prescription drug abuse as reported in RADARS<sup>®</sup> System Poison Center Data. College on Problems of Drug Dependence Annual Meeting. Reno, NV. June 2009. **POSTER** 

# **Drug Information Association**



Lindholm A, Varughese S, Rosen S, Sembower M, Ertischek M, St. Jean E, Schnoll S. Innovative use of multiple surveillance data sources for detection of misuse, abuse and diversion in the Risk Management Plan (RMP) of stimulant medications used in ADHD. Drug Information Association 2009 Annual Meeting. San Diego, CA. June 2009. **POSTER** 

### Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials

Dart RC. Poison Center Data to Assess the Relative Abuse Rates of Prescription Opioids. Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials Meeting. Arlington, VA. June 2009. INVITED PRESENTATION

### North American Congress of Clinical Toxicology

Hedge MW, Smolinski S, Bailey JE, Dart RC, RADARS System Poison Center Group. Ototoxicity of prescription opioids. North American Congress of Clinical Toxicology Annual Meeting. San Antonio, TX. September 2009. **POSTER** 

Sweet LE, Zolot L, Bailey JE, Dart RC, RADARS® System Poison Center Group. Where do calls come from? Analysis of RADARS<sup>®</sup> System Opioid and Stimulant Poison Center (PC) mentions by caller site and intent. North American Congress of Clinical Toxicology Annual Meeting. San Antonio, TX. September 2009. **POSTER** 

#### NJ Pain Conference

Cicero TJ. Post-Marketing Surveillance of Controlled Substance Abuse and the Emergence of REMS. NJ Pain Conference. New Jersey. September 2009. INVITED PRESENTATION

## US Psychiatric and Mental Health

Varughese S, Rosen S, Lindholm A, Ertischek MD, Sembower MA, Sweeney CT, Shiffman S, Schnoll S. Surveillance of non-medical use with Lisdexamfetamine Dimesylate, a pro-drug stimulant for the treatment of ADHD. US Psychiatric and Mental Health Annual Congress. Las Vegas, NV. May 2009. **POSTER** 

#### 2008

# American Academy of Addiction Psychiatry

Kirtland MN, Bailey JE, Dart RC. Prescription opioid associated death rates using RADARS<sup>®</sup> System Data. American Academy of Addiction Psychiatry Annual Meeting. Boca Raton, FL. December 2008. ORAL PRESENTATION

Montoya AM, Bailey JE, Dart RC. Current nonmedical prescription drug use among college students: Analysis of RADARS<sup>®</sup> System Data. American Academy of Addiction Psychiatry Annual Meeting. Boca Raton, FL. December 2008. ORAL PRESENTATION

#### American Psychiatric Association

Kirtland MN, Bailey JE, Dart RC. Suicide and gender: Characterization using RADARS<sup>®</sup> System Poison Center Data. American Psychiatric Association Annual Meeting. Washington, DC. May 2008. **POSTER** 

#### American Society of Addiction Medicine

Dart RC. Buprenorphine Misuse, Abuse and Diversion in the RADARS® System. American Society of Addiction Medicine June 2008. INVITED PRESENTATION

#### **Center for Substance Abuse Treatment**

Dasgupta N. RADARS® System Subutex & Suboxone: How Much is Prescribed vs. Abuse/Diversion Reports. Center for Substance Abuse Treatment. Washington, DC. February 2008. INVITED PRESENTATION

# College on Problems of Drug Dependence



Campagna E, Bailey JE, Dart RC. Detection of prescription opioid abuse/diversion using Research Abuse Diversion and Addition-Related Surveillance (RADARS<sup>®</sup>) System Data. College on Problems of Drug Dependence Annual Meeting. San Juan, PR. June 2008. **POSTER** 

Montoya AM, Heltshe SL, Dart RC. Spatial analysis of RADARS<sup>®</sup> System Data to identify geographic hot spots of prescription opioid-abuse. College on Problems of Drug Dependence Annual Meeting. San Juan, PR. June 2008. **POSTER** 

Parrino M, Rosenblum A, Fong C, Maxwell C, Magura S. Distance traveled and cross state commuting among patients in Opioid Agonist Treatment Programs (OTPs). College on Problems of Drug Dependence Annual Meeting. San Juan, PR. June 2008. **POSTER** 

Spaeth AL, Bailey JE, Dart RC. Characterization of buprenorphine abuse using RADARS<sup>®</sup> System Poison Center Data. College on Problems of Drug Dependence Annual Meeting. San Juan, PR. June 2008. **ORAL PRESENTATION** 

Spiller HA, Lorenz D, Bailey JE, Dart RC. Epidemiological trends in prescription drug misuse and abuse. College on Problems of Drug Dependence Annual Meeting. San Juan, PR. June 2008. **POSTER** 

Zosel AE, Campagna E, Bailey JE, Dart RC. Demographic variables associated with prescription opioid abuse and diversion detected by the RADARS<sup>®</sup> System. College on Problems of Drug Dependence Annual Meeting. San Juan, PR. June 2008. **POSTER** 

#### National Association of State Controlled Substance Authorities

Dart RC. Pharmacovigilance of Prescription Drugs: Misuse, Abuse and Diversion in the RADARS® System. National Association of State Controlled Substance Authorities Conference. October 2008. INVITED PRESENTATION

#### North American Congress of Clinical Toxicology

Kirtland MN, Lemon S, Bailey JE, Dart RC, RADARS® System Poison Center Group. Effectiveness of a poison center intervention on product coding. North American Congress of Clinical Toxicology Annual Meeting. Toronto, Canada. September 2008. **POSTER** 

Varney SM, Buchanan JA, Lavonas EJ, Campagna EJ, Bailey JE, Dart RC. How opioid-acetaminophen overdose patients die. North American Congress of Clinical Toxicology Annual Meeting. Toronto, Canada. September 2008. **POSTER** 

Zosel A, Bailey JE, Dart RC. Propoxyphene: a drug with unfavorable risk-benefit characteristics. North American Congress of Clinical Toxicology Annual Meeting. Toronto, Canada. September 2008. **POSTER** 


#### 2007

#### American Pain Society

Kirtland MN, Bailey JE, Dart RC. Prescription opioid misuse and abuse: Surveillance by the RADARS<sup>®</sup> System Poison Centers. American Pain Society Annual Meeting. Washington, DC. May 2007. **POSTER** 

#### American Public Health Association

Dart RC, Campagna E, Bailey JE, Kirtland M, Spiller HA. The effectiveness of the Kentucky operation UNITE (Unlawful Narcotics Investigations, Treatment and Education) as evaluated by RADARS<sup>®</sup> System Poison Centers. American Public Health Association Annual Meeting. Washington, DC. November 2007. **POSTER** 



Dasgupta N, Bailey JE, Dart RC, Funk MJ. Poison center exposure calls predict mortality due to prescription opioid poisoning. American Public Health Association Annual Meeting. Washington, DC. November 2007. **ORAL PRESENTATION** 

#### Center for Substance Abuse Treatment

Dart RC. RADARS® System "Fentanyl Study". Center for Substance Abuse Treatment Washington, DC. August 2007. INVITED PRESENTATION

Dart RC. RADARS® System "Methadone Study". Center for Substance Abuse Treatment. Washington, DC. July 2007. INVITED PRESENTATION

### College on Problems of Drug Dependence

Bailey JE, Cram LM, Dart RC. Description of buprenorphine, methadone, hydrocodone and oxycodone abuse and diversion rates using RADARS<sup>®</sup> System Data. College on Problems of Drug Dependence Annual Meeting. Quebec City, Canada. June 2007. (*Presented by LM Cram*). ORAL PRESENTATION

Campagna E, Bailey JE, Dart RC. Prescription opioid abuse in urban versus rural communities using RADARS<sup>®</sup> System Data. College on Problems of Drug Dependence Annual Meeting. Quebec City, Canada. June 2007. **POSTER** 

Haddox JD, Fitzgerald JP, Kline AT, Smith MY. Characterizing the nonmedical use/abuse and diversion of opioid analgesics in 2006: findings from ethnographic field research. College on Problems of Drug Dependence Annual Meeting. Quebec City, Canada. June 2007. **POSTER** 

Inciardi JA, Surratt H, Kurtz SP, Cicero TJ. The diversion of generic prescription drugs. College on Problems of Drug Dependence Annual Meeting. Quebec City, Canada. June 2007. **POSTER** 

Kline AT, Smith MY, Fitzgerald JP, Haddox JD, Bailey JE. A comparison of NSDUH results and RADARS<sup>®</sup> System Poison Center Network results for the non-medical use of opioid analgesics, 2003-2004. College on Problems of Drug Dependence Annual Meeting. Quebec City, Canada. June 2007. **POSTER** 

Rosenblum A, Parrino M, Schnoll SH, Fong C, Maxwell C, Cleland CM, Haddox JD, Magura S. Prescription opioid abuse among patients enrolling in methadone maintenance treatment. College on Problems of Drug Dependence Annual Meeting. Quebec City, Canada. June 2007. **POSTER** 

# North American Congress of Clinical Toxicology

Campagna E, Bailey JE, Dart RC, RADARS® System Poison Center Group. Fentanyl patch abuse using RADARS<sup>®</sup> System Poison Center Data. North American Congress of Clinical Toxicology Annual Meeting. New Orleans, LA. October 2007. **POSTER** 

# Office of National Drug Control Policy


Dart RC. RADARS® System. Office of National Drug Control Policy Act 109th Congress. Washington, DC. April 2007. INVITED PRESENTATION

2006

#### American College of Emergency Physicians

Bailey JE, Dart RC. Exposures to oxycodone: Demographic differences by formulation. American College of Emergency Physicians Annual Meeting. New Orleans, LA. October 2006. **POSTER** 

#### College on Problems of Drug Dependence



Dart RC, Hughes AA, Reporting for the RADARS<sup>®</sup> System Poison Control Centers. Adolescent prescription opioid abuse and misuse: Surveillance by Poison Centers. College on Problems of Drug Dependence Annual Meeting. Scottsdale, AZ. June 2006. **POSTER** 

Fitzgerald JP, Smith MY, Haddox JD, Kline AT. Characterizing opioid analgesic abuse: findings from ethnographic field research. College on Problems of Drug Dependence Annual Meeting. Scottsdale, AZ. June 2006. **POSTER** 

Haddox JD, Smith MY, Colucci S, Rosenblum A, Fong C, Maxwell C, Parrino M. Pain as a reason for seeking admission to methadone treatment. College on Problems of Drug Dependence Annual Meeting. Scottsdale, AZ. June 2006. **POSTER** 

Inciardi JA, Surratt HL. The diversion of prescription opioids in the US. College on Problems of Drug Dependence Annual Meeting. Scottsdale, AZ. June 2006. **POSTER** 

Kline AT, Smith MY, Haddox JD, Rosenblum A, Fong C, Parrino, M, Maxwell C. Abuser-reported sources of illegally obtained opioid analgesic medications. College on Problems of Drug Dependence Annual Meeting. Scottsdale, AZ. June 2006. **POSTER** 

Smith MY, Irish W, Wang J, Haddox JD, Dart RC. Relative rate of opioid analgesic abuse in communities in the US. College on Problems of Drug Dependence Annual Meeting. Scottsdale, AZ. June 2006. **POSTER** 

#### **Colorado Public Health Association**

Bailey JE, Bogdan GM, Dart RC. Adolescent prescription opioid abuse and misuse. Colorado Public Health Association Annual Meeting. Vail, CO. August 2006. **POSTER** 

#### **Drug Information Association**

Bailey JE, Bogdan GM, Dart RC, Reporting for the RADARS<sup>®</sup> System Poison Control Centers. Demographic differences in the misuse and abuse of oxycodone formulations: Poison center surveillance. Drug Information Association Annual Meeting. Philadelphia, PA. June 2006. **POSTER** 

#### North American Congress of Clinical Toxicology

Bailey JE, Bogdan GM, Dart RC, RADARS® System Poison Center Group. Extended release versus immediate release morphine: Differences in abuse and medical outcomes. North American Congress of Clinical Toxicology Annual Meeting. San Francisco, CA. October 2006. **POSTER** 

Balentine B, Slattery A, Liebelt E. Is there an Association between Human Opioid Exposures and Drug Identification Calls Reported to a Regional Poison Control Center and Prohibited Alcohol-Sales Counties? North American Congress of Clinical Toxicology Annual Meeting. San Francisco, CA. October 2006. **POSTER** 

#### 2005


#### American Public Health Association

Dart RC, Hughes AA. Public health disparities in rural areas: High rates of prescription opioid abuse? American Public Health Association Annual Meeting. Philadelphia, PA. December 2005. **POSTER** 

Hughes AA, Dart RC. Prescription drug abuse epidemic: Surveillance of opioid abuse using poison centers. American Public Health Association Annual Meeting. Philadelphia, PA. December 2005. **ORAL PRESENTATION** 

#### College on Problems of Drug Dependence

Berry TR, Schnoll S. A qualitative analysis of RADARs System key informant interviews. College on Problems of Drug Dependence Annual Meeting. Orlando, FL. June 2005. **POSTER** 



Dasgupta N, Brownstein J, Schnoll SH. Geospatial modeling of disparate data sources on prescription opioid abuse. College on Problems of Drug Dependence Annual Meeting. Orlando, FL. June 2005. **POSTER** 

Graham A, Smith MY, Haddox JD, Wright C. Reducing the potential for diversion of prescription opioids: Intervention options. College on Problems of Drug Dependence Annual Meeting. Orlando, FL. June 2005. **POSTER** 

Hughes AA, Dart RC. Surveillance of the RADARS<sup>®</sup> System by poison control centers. College on Problems of Drug Dependence Annual Meeting. Orlando, FL. June 2005. **POSTER** 

Kline A, Schnoll S. RADARs System-convergence/divergence of attitudes from law enforcement and drug treatment centers regarding prescription opioid abuse. College on Problems of Drug Dependence Annual Meeting. Orlando, FL. June 2005. **POSTER** 

Senay EC, Geller A, Woody G, Dart RC, Hughes A, Smith MY. Abuse, dependence and misuse of prescription opioid analgesics, benzodiazepines and carisoprodol in 7792 calls to poison control centers. College on Problems of Drug Dependence Annual Meeting. Orlando, FL. June 2005. **POSTER** 

Smith MY, Dart RC, Hughes A, Geller A, Senay EC, Woody G. Clinician validation of poison control center intentional exposure cases involving prescription opioids. College on Problems of Drug Dependence Annual Meeting. Orlando, FL. June 2005. **POSTER** 

#### College on Problems of Drug Dependence Impact Conference

Haddox JD, Schnoll SH. The standards for risk management plans for high abuse potential medications. College on Problems of Drug Dependence Impact Conference. Washington, DC. April 2005. **POSTER** 

Smith MY. Measuring rates of nonmedical use - Dimensions and denominators. College on Problems of Drug Dependence Impact Conference. Washington, DC. April 2005. **POSTER** 

#### **Colorado Public Health Association**

Hughes AA, Dart RC. Demographic differences of the misuse and abuse of oxycodone formulations. Colorado Public Health Association Annual Meeting. Denver, CO. September 2005. **POSTER** 

#### North American Congress of Clinical Toxicology

Hughes AA, Dart RC, Bailey JE, RADARS® System Poison Control Centers. Lick or stick: The common routes of the misuse and abuse of fentanyl. North American Congress of Clinical Toxicology Annual Meeting. Orlando, FL. September 2005. **POSTER** 

2004

#### North American Congress of Clinical Toxicology

Hughes AA, Dart RC, RADARS<sup>®</sup> System Poison Control Centers. Seasons of abuse? Temporal trends of prescription opioids. North American Congress of Clinical Toxicology Annual Meeting. Seattle, WA. September 2004. **POSTER** 

2003

#### North American Congress of Clinical Toxicology

Hughes AA, Bogdan GM, Dart RC. Comparative rates of OxyContin<sup>®</sup> abuse: Anecdotal highs. North American Congress of Clinical Toxicology Annual Meeting. Chicago, IL. September 2003. **POSTER** 



*North American Congress of Clinical Toxicology* Hughes AA, Bogdan GM, Bond R, Dart RC. Increase in OxyContin<sup>®</sup> abuse or media hype? North American Congress of Clinical Toxicology Annual Meeting. Palm Springs, CA. September 2002. **POSTER** 



# **Technical Reports**

2019

Amioka E, Burnham RI, Kreider SED, Black JC, Severtson SG, Dart RC (2019). Multiple imputation of missing data in the Poison Center Program. RADARS<sup>®</sup> System Technical Report, 2019-Q2.

Black JC, Rockhill K, Forber A, Amioka E, May KP, Haynes CM, Dart RC (2019). Redesign of Survey of Non-Medical Use of Prescription Drugs Program improves benchmark estimates. RADARS<sup>®</sup> System Technical Report, 2019-Q1.

Seidel Halmo L, Rockhill K, Black JC, Dart RC, Iwanicki JL (2019). Prevalence of illicit drug use and non-medical prescription drug use among pregnant women in the United States. RADARS® System Technical Report, 2019- Q4.

Severtson SG, Kreider SED, Olsen H, Ellis MS, Cicero TJ, Dart RC (2019). Changes in the prevalence of methamphetamine use among individuals entering medication-assisted treatment programs for opioid use disorders. RADARS<sup>®</sup> System Technical Report, 2019-Q3.

#### 2018

Iwanicki JL, Buchanan J, Black JC, Dart RC (2018). Matching poison center deaths with death certificate data. RADARS<sup>®</sup> System Technical Report, 2018-Q4

Severtson SG, Bau G, Dart RC (2018). Pediatric suspected suicide exposures involving prescription stimulants are increasing faster than stimulant prescriptions. RADARS<sup>®</sup> System Technical Report, 2018-Q2.

Severtson SG, Iwanicki JL, Margolin, ZR, Dart RC (2018). Increases in natural and semi-synthetic opioid deaths coincide with concurrent heroin and illicit fentanyl use. RADARS<sup>®</sup> System Technical Report, 2018-Q1.

Severtson SG, Schwarz J, Dasgupta N, Dart RC (2018). Rates of abuse for opioids with low dispensing are overestimated due to careless response patterns on Treatment Center Program surveys. RADARS<sup>®</sup> System Technical Report, 2018-Q3.

2017

Black JC, Bau G, Bucher Bartelson B, Dasgupta N, Dart RC, Green JL (2017). Comparison of Population Rate Trends between the National Vital Statistics System and the RADARS<sup>®</sup> System Medical Examiner Program. RADARS<sup>®</sup> System Technical Report, 2017-Q2.

Dasgupta N, Bailey JE, Dart RC (2017). Implications of Declining Poison Center Case Volume on Drug Abuse Trend Monitoring. RADARS<sup>®</sup> System Technical Report, 2017-Q3.

Severtson SG, Olsen HA, Dart RC (2017). Prevalence of inhalation and injection use among intentional abuse exposure cases involving methylphenidate in the Poison Center Program. RADARS<sup>®</sup> System Technical Report, 2017-Q4.

Severtson SG, Olsen HA, Ellis MS, Cicero TJ, Green JL, Dart RC. (2017). Prevalence of chewing, snorting, injecting, and smoking prescription opioid tablets/capsules among individuals entering treatment for an opioid use disorder. RADARS<sup>®</sup> System Technical Report, 2017-Q1.



Bau G, Bucher Bartelson B, Severtson SG, Green JL, Dart RC. (2016). Comparison of population rate trends between the Drug Abuse Warning Network (DAWN) and the RADARS<sup>®</sup> System Poison Center Program. RADARS<sup>®</sup> System Technical Report, 2016-Q4.

Fischer L, McDaniel HA, Severtson SG, Green JL, Dart RC (2016). Effect of hydrocodone rescheduling on intentional abuse exposures reported to poison centers. RADARS<sup>®</sup> System Technical Report, 2016-Q1.

McDaniel HA, Severtson SG, Bucher Bartelson B, Green JL, Dart RC (2016). Comparing Prescription Opioids, Methadone, and Heroin Endorsement Rates from the Treatment Episode Data Set to the RADARS<sup>®</sup> System Treatment Center Programs, RADARS<sup>®</sup> System Technical Report, 2016-Q3.

Severtson SG, McDaniel HA, Bucher Bartelson B, Green JL, Ellis M, Fong C, Cicero T, Dart RC (2016). Declines in the abuse of extended release morphine tablets and capsules following the reformulation of OxyContin<sup>®</sup>. RADARS<sup>®</sup> System Technical Report, 2016-Q2.

#### 2015

Cicero TJ, Ellis MS, Harney J (2015). Abuse prevalence and preference of immediate release versus extended release opioids. RADARS® System Technical Report, 2015-Q3.

Lebin JA, Murphy DL, Severtson SG, Dasgupta N, Dart RC (2015). Reduced Street Price and Quantity Discounts for Diverted Extended Release OxyContin ER and Opana ER Following Crush Resistant Reformulation. RADARS® System Technical Report, 2015-Q2.

Le Lait MC, Bucher-Bartelson B, Green JL, Dart RC (2015). Number of Prescription Opioid Tablets/Capsules Ingested for Intentional Abuse Exposures Reported to Poison Centers. RADARS® System Technical Report, 2015-Q4.

Murphy DL, Lebin JA, Severtson SG, Dart RC (2015). Comparative Rates of Mortality and Severe Medical Effect Among Commonly Prescribed Opioid Analgesics: Calls to US Poison Centers Reporting Opioid Overdose Due to Intentional Abuse and Misuse Exposures. RADARS® System Technical Report, 2015-Q1.

#### 2014

Dart RC, Martinez E, Severtson SG, Menone CM, Dasgupta N (2014). Appearance of Canadian Oxycodone Extended Release Products in the United States. RADARS System Technical Report, 2014-Q1.

Le Lait MC, Severtson SG, Bucher-Bartelson B, Dart RC (2014). Prescription Opioid Death Rates by Gender using Data from the RADARS® System Poison Center Program. RADARS® System Technical Report, 2014Q4.

Ronk C, Bucher Bartelson B, Severtson SG, Green JL, Dart RC (2014). Opioid-Related Mortality: National Vital Statistics System versus RADARS® Poison Center Program. RADARS® System Technical Report, 2014Q3.

Ronk C, Severtson SG, Le Lait C, West N, Bucher Bartelson B, Dart RC (2014). Choice of Denominator in the Calculation of Opioid Abuse Rates. RADARS® System Technical Report, 2014Q2.

#### 2013

Le Lait C, Bucher Bartelson B, Severtson G, Dart R (2013). Comparison of drug diversion street price and StreetRx programs. RADARS System Technical Report. 2013-Q3.



Le Lait MC, Severtson G, Bucher Bartelson B (2013). Comparison of Unique Recipients of Dispensed Drugs and Total Number of Prescription Filled in the Calculation of Abuse Rates. RADARS System Technical Report, 2013-Q2.

Lowitz K, Le Lait MC, Severtson SG, Dart RC (2013). Kentucky – Impact of Opioid Abuse Deterrent Policies. RADARS System Technical Report, 2013-Q1.

Severtson SG, Bucher Bartelson B, Green JL, Dart RC (2013). Impact of tamper resistant formulations on rates of abuse of schedule II opioids. RADARS System Technical Report, 2013-Q4.

#### 2012

Bucher Bartelson B, Droz D, Severtson G, Le Lait C, Dart R (2012). A comparison of three measures of prescription opioid availability. RADARS System Technical Report, 2012-Q4-2.

Davis, JM; Severtson, SG; Bartelson, B.B & Dart, R. (2012). Prescription opioid abuse and misuse rates from RADARS are highly correlated with rates from the Drug Abuse Warning Network. RADARS System Technical Report, 2012-Q3.

Severtson, SG; Bartelson, B.B. & Dart, R. (2012). Age trends in the abuse of prescription opioids. RADARS System Technical Report, 2012-Q4-1.

Severtson, SG; Bucher-Bartelson, B; Davis, J; & Dart, R. (2012). Fatalities and polysubstance use among prescription opioid abuse cases in the RADARS System Poison Center Program. RADARS System Technical Report, 2012-Q1.

Severtson, SG; Davis, J; Bartelson, B.B. & Dart, R. (2012). Use of unique recipients of dispensed drug (URDD) in assessing the burden of abuse, misuse, and diversion of prescription opioid products. RADARS System Technical Report, 2012-Q2.



# **Book Chapters**

Niemi J, Smith M, Banks D. *Biosurveillance and Biosecurity: Lecture Notes in Bioinformatics*. Ed. D Zeng, H Chen, H Rolka, and W Lober. New York: Springer, 2008. 131-142.